Nanobody-drug adducts and uses thereof

CN118946591APending Publication Date: 2024-11-12CHILDRENS MEDICAL CENT CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380028668.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-08
Filing Date
2023-01-19
Publication Date
2024-11-12

Smart Images

  • Figure CN118946591A_ABST
    Figure CN118946591A_ABST
Patent Text Reader

Abstract

Provided herein are conjugate molecules comprising an antibody or antibody fragment capable of binding to a polyclonal immunoglobulin in a subject. Such conjugates can be used to recruit immune cells of the subject to one or more cell types targeted by the conjugate. Also provided herein are compositions comprising the conjugates, including pharmaceutical compositions that may be administered to a subject for the purpose of treating or preventing a disease.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 63 / 300,995, filed on January 19, 2022, and U.S. Provisional Application No. 63 / 423,667, filed on November 8, 2022; the entire contents of each of the said U.S. Provisional Applications are incorporated herein by reference.

[0003] Federally funded research

[0004] This invention was made with government support under Grant No. AI 150593 awarded by the National Institutes of Health. The government has certain rights in this invention. Background Art

[0005] Crystallizable fragment (Fc) receptor is a kind of immunoglobulin receptor, is located on the cell membrane of many immune cell types, including macrophages, dendritic cells, natural killer cells, neutrophils, basophils, eosinophils and mast cells. These cells usually have only limited ability to directly target antigens (such as antigens on the surface of viruses, microbial pathogens and cancer cells). However, these immune cells can bind to polyclonal antibodies through the Fc receptors on their surface. These polyclonal antibodies can then bind to antigens on the surface of cells (including bacteria, parasites and fungi) or viruses, thereby enabling immune cells to act on these targets. Summary of the Invention

[0006] The immune system comprises a variety of specialized cell types, many of which are responsible for active targeting and eliminating viruses, foreign cells, particularly pathogenic microorganisms (e.g., bacteria, parasites and fungi), and non-exogenous but cells that have undergone some harmful phenotypic changes (e.g., damaged cells, virus-infected cells and transformed cells, such as cancer cells). Although immune cells protect their hosts from the infringement of these widespread pathogenic cell types or harmful cell types, these immune cells cannot directly bind to their targets usually. On the contrary, many specialized immune cells bind to the immunoglobulins produced by their hosts through the Fc receptors on their surfaces, and the immunoglobulins are specific to the specific antigens on the surface of the target cells or pathogens. Although this system can be effectively immunized for a wide range of possible targets, it is limited to the amount of immunoglobulins that are specific to a specific antigen that are present in the host at any given time. The level of immunoglobulins that are specific to a given target antigen needs to be exposed to these antigens in advance, for example, by natural infection or by intentional immunity with the specific antigens.

[0007] The molecules that enhance the interaction between immune cells and potential targets (regardless of the specificity of the host immunoglobulin) will be particularly useful for the treatment and prevention of various diseases. A strategy for designing and producing such molecules is described herein, which involves conjugating a first agent with a specific second agent to an antigen on the surface of a cell or pathogen to the immunoglobulin produced by the host. By selecting the first agent specifically bound to a structural feature (such as κ light chain or λ light chain) shared with a wide range of host immunoglobulins, such conjugates can be combined with any one of the host immunoglobulins in a virus or cell surface antigen and a wide range of host immunoglobulins, and the immunoglobulin can then be combined with Fc receptor positive immune cells (such as natural killer (NK) cells, macrophages or other cells of myeloid lineage). In this way, these conjugates can be used to recruit Fc receptor positive immune cells to target cells or pathogens, and are independent of the clonality or specificity of the immunoglobulin to which immune cells are subsequently connected to the target. These conjugates can be customized to target any conceivable antigen for immune cell targeting, and can be used to enhance or trigger the immune response of specific cells or pathogens in an object.

[0008] Some aspects of the present disclosure provide a conjugate comprising a first agent that binds to an immunoglobulin and a second agent that binds to a target on the surface of a cell or pathogen, wherein the first agent and the second agent are covalently conjugated via a linker in a chemical reaction.

[0009] In some embodiments, the first agent is an antibody fragment comprising a variable region capable of binding to an antigen. In some embodiments, the antibody fragment comprises a heavy chain variable region. In some embodiments, the first agent is a single domain antibody fragment. In some embodiments, the immunoglobulin recruited by the conjugate comprises an immunoglobulin kappa light chain or an immunoglobulin lambda light chain. In some embodiments, the immunoglobulin kappa light chain is a human immunoglobulin kappa light chain, and the immunoglobulin lambda light chain is a human immunoglobulin lambda light chain. In some embodiments, the first agent binds to the human immunoglobulin kappa light chain.

[0010] In some embodiments, the second agent comprises a small molecule, a peptide, a protein, a carbohydrate, a lipid, a nucleotide, a nucleic acid, an oligonucleotide, an aptamer, or an antibody. In some embodiments, the second agent is an antibody, and the antibody is a single domain antibody. In some embodiments, the second agent has a therapeutic effect when administered to a subject.

[0011] In some embodiments, the linker comprises a cleavable linker or a non-cleavable linker. In some embodiments, the linker comprises a cleavable linker. In some embodiments, the cleavable linker is a peptide linker, a disulfide linker, or a hydrazone linker.

[0012] In some embodiments, the cell is a cell infected by a pathogen, a cancer cell, a transformed cell, a healthy cell, a cell that is undergoing or has undergone a phenotypic change in response to cellular stress. In some embodiments, the pathogen is a virus, a bacterium, a parasite, or a fungus.

[0013] In some embodiments, the pathogen is a virus selected from the group consisting of influenza virus, coronavirus, adenovirus, enterovirus, rotavirus, norovirus, herpes virus, lentivirus, poxvirus, paramyxovirus, rhabdovirus, arenavirus, flavivirus, togavirus, hantavirus, pneumovirus, or ebolavirus.

[0014] In some embodiments, the influenza virus is influenza A virus or influenza B virus. In some embodiments, the second agent binds to influenza virus neuraminidase or influenza virus hemagglutinin. In some embodiments, the second agent comprises a small molecule that binds to influenza virus neuraminidase. In some embodiments, the second agent comprises zanamivir or an analog thereof. In some embodiments, the linker is a triglycine dibenzylcyclooctyne (DBCO) linker. In some embodiments, the second agent comprises an antibody or antibody fragment that binds to influenza virus neuraminidase.

[0015] In some embodiments, the coronavirus is a beta coronavirus. In some embodiments, the beta coronavirus is Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome (SARS)-related Coronavirus (SARS-CoV)-1, or SARS-CoV-2. In some embodiments, the second agent binds to the MERS-CoV spike protein, the SARS-CoV-1 spike protein, or the SARS-CoV-2 spike protein. In some embodiments, the second agent binds to the MERS-CoV spike protein receptor binding domain (RBD), the SARS-CoV-1 spike protein RBD, or the SARS-CoV-2 spike protein RBD.

[0016] In some embodiments, the lentivirus is human immunodeficiency virus (HIV).In some embodiments, the second agent binds to HIV envelope glycoprotein gp120.

[0017] In some embodiments, the pneumovirus is human respiratory syncytial virus (RSV).In some embodiments, the second agent binds to the RSV fusion (F) protein.

[0018] In some embodiments, the pathogen is a bacterium selected from the group consisting of Pasteurella species, Staphylococcus species, Streptococcus species, Bacillus species, Corynebacterium species, Diphtheroids species, Listeria species, Erysipelothrix species, Clostridium species, Neisseria species, Branhamella species, Escherichia species, Enterobacter species, Proteus species, Pseudomonas species, Klebsiella species, Salmonella species, Shigella species, Serratia species, Acinetobacter species,

[0014] The present invention also includes but is not limited to: bacterial pathogens, fungi, and fungi such as bacterium, fungi, and fungi such as bacterium, fungi, and fungi such as bacterium, fungi, and fungi such as bacterium, and ...

[0019] In some embodiments, the pathogen is a parasite selected from the group consisting of Plasmodium species, Trypanosoma species, Toxoplasma species, Leishmania species, or Cryptosporidium species. In some embodiments, the Plasmodium is Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, Plasmodium knowlesi, Plasmodium ovale curtisi, or Plasmodium ovale wallikeri. In some embodiments, the second agent binds to a Plasmodium surface protein. In some embodiments, the Plasmodium surface protein is merozoite surface protein 1 (MSP-1). In some embodiments, the second agent is an antibody that binds to MSP-1, optionally wherein the antibody is a nanobody. In some embodiments, the antibody comprises CDR-H1, CDR-H2, and CDR-H3 of any one of the antibodies listed in Table 1. In some embodiments, the antibody comprises an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, or at least 99%) identical to any one of SEQ ID NOs: 6-17. In some embodiments, the antibody comprises the amino acid sequence of any one of SEQ ID NOs: 6-17.

[0020] In some embodiments, the cancer cell is a blood cancer cell, a lung cancer cell, a breast cancer cell, a brain cancer cell, a gastrointestinal cancer cell, a liver cancer cell, a kidney cancer cell, a bladder cancer cell, a pancreatic cancer cell, an ovarian cancer cell, a testicular cancer cell, a prostate cancer cell, an endometrial cancer cell, a muscle cancer cell, a bone cancer cell, a neuroendocrine cancer cell, a connective tissue cancer cell, a head and neck cancer cell, or a skin cancer cell. In some embodiments, the second agent binds to a tumor-associated antigen. In some embodiments, the tumor-associated antigen includes an MHC class I polypeptide-related sequence A (MICA) protein, an MHC class I polypeptide-related sequence B (MICB) protein, a folate receptor, a fibronectin splice variant, an epidermal growth factor receptor (EGFR), a human epidermal growth factor receptor 2 (HER2), a hepatocyte growth factor receptor (HGFR), a vascular endothelial growth factor receptor 2 (VEGFR-2), a CXC chemokine receptor type 4 (CXCR4), a urokinase plasminogen activator surface receptor (uPAR), a follicle-stimulating hormone receptor (FSHR), an epithelial cell adhesion molecule (EpCAM), an epithelial cadherin (ECAD), a carcinoembryonic antigen (CEA), or a mesothelin (MSLN). In some embodiments, the second agent is an antibody that binds to MICA, optionally wherein the antibody is a nanobody. In some embodiments, the antibody comprises CDR-H1, CDR-H2, and CDR-H3 of any one of the antibodies listed in Table 2. In some embodiments, the antibody comprises the amino acid sequence of any one of SEQ ID NOs: 19-27.

[0021] In some embodiments, the cell is a cancerous bone marrow cell or a healthy bone marrow cell. In some embodiments, the bone marrow-associated antigen is cluster of differentiation antigen 45 (CD45).

[0022] In some embodiments, the cell is a cancerous immune cell or a healthy immune cell. In some embodiments, the cell is a cancerous T cell or B cell, or a healthy T cell or B cell. In some embodiments, the second agent binds to an immune cell-associated antigen. In some embodiments, the immune cell-associated antigen is a cluster of differentiation antigen 4 (CD4), a cluster of differentiation antigen 8 (CD8), a T cell receptor (TCR), or a B cell receptor (BCR).

[0023] In some embodiments, the conjugate provides a therapeutic effect when administered to a subject. In some embodiments, the conjugate enhances the association between one or more immune cells expressing a crystallizable fragment (Fc) receptor and the cell or pathogen when administered to a subject. In some embodiments, the conjugate causes killing of the cell or pathogen when administered to a subject. In some embodiments, the conjugate causes inactivation of the cell or pathogen when administered to a subject. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.

[0024] In another aspect, the present disclosure provides a composition comprising any of the conjugates described herein. In some embodiments, such a composition further comprises a pharmacologically acceptable excipient.

[0025] In another aspect, the present disclosure provides a method for enhancing an immune response of a subject to a cell or pathogen, the method comprising administering to the subject an effective amount of any one of the conjugates or compositions described herein. In some embodiments, the cell is a cell infected by a pathogen, a cancer cell, a transformed cell, a healthy cell, a cell that is undergoing or has undergone a phenotypic change in response to cellular stress. In some embodiments, the pathogen is a virus, a bacterium, a parasite, or a fungus. In some embodiments, the cell is a cell of the subject.

[0026] In some embodiments, the pathogen is a virus selected from the group consisting of influenza virus, coronavirus, adenovirus, enterovirus, rotavirus, norovirus, herpes virus, lentivirus, poxvirus, paramyxovirus, rhabdovirus, arenavirus, flavivirus, togavirus, hantavirus, pneumonia virus, or Ebola virus. In some embodiments, the virus is influenza A virus or influenza B virus. In some embodiments, the virus is Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome (SARS)-associated coronavirus (SARS-CoV)-1, or SARS-CoV-2. In some embodiments, the virus is human immunodeficiency virus (HIV). In some embodiments, the virus is human respiratory syncytial virus (RSV).

[0027] In some embodiments, the pathogen is a bacterium selected from the group consisting of Pasteurella, Staphylococcus, Streptococcus, Bacillus, Corynebacterium, Diphtheroids, Listeria, Erysipelothrix, Clostridium, Neisseria, Branhamella, Escherichia, Enterobacter, Proteus, Pseudomonas, Klebsiella, Salmonella, Shigella, Serratia, Acinetobacter, Haemophilus, Brucella, Yersinia, Francisella, Pasteurella, Vibrio cholerae, Flavobacterium, Pseudomonas, Campylobacter, Bacteroides, Fusobacterium, Scabiei, Streptobacillus, or Legionella.

[0028] In some embodiments, the pathogen is a parasite selected from the group consisting of Plasmodium, Trypanosoma, Toxoplasma, Leishmania, or Cryptosporidium. In some embodiments, the parasite is Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, Plasmodium knowlesi, Plasmodium ovale subsp. coli, or Plasmodium ovale subsp. worleri.

[0029] In some embodiments, the cancer cell is a blood cancer cell, a lung cancer cell, a breast cancer cell, a brain cancer cell, a gastrointestinal cancer cell, a liver cancer cell, a kidney cancer cell, a bladder cancer cell, a pancreatic cancer cell, an ovarian cancer cell, a testicular cancer cell, a prostate cancer cell, an endometrial cancer cell, a muscle cancer cell, a bone cancer cell, a neuroendocrine cancer cell, a connective tissue cancer cell, a head and neck cancer cell, or a skin cancer cell.

[0030] In some embodiments, the cell is a cancerous bone marrow cell or a healthy bone marrow cell.

[0031] In some embodiments, the cell is a cancerous immune cell or a healthy immune cell. In some embodiments, the cell is a cancerous T cell or B cell, or a healthy T cell or B cell.

[0032] In some embodiments, the immune response comprises an innate immune response. In some embodiments, the conjugate binds to the cell or pathogen and to the immunoglobulin of the subject, wherein the immunoglobulin further binds to the immune cell of the subject, and the immune cell expresses a crystallizable fragment (Fc) receptor on its surface. In some embodiments, the immunoglobulin of the subject comprises an immunoglobulin kappa light chain or an immunoglobulin lambda light chain. In some embodiments, the immunoglobulin of the subject comprises an immunoglobulin kappa light chain. In some embodiments, the immune cell is a macrophage, a dendritic cell, a natural killer cell, a neutrophil, a basophil, an eosinophil, or a mast cell. In some embodiments, the administration induces the immune cell to produce one or more cytokines or chemokines. In some embodiments, the one or more cytokines or chemokines are proinflammatory cytokines or chemokines. In some embodiments, the administration induces phagocytosis of the cell or pathogen by the immune cell. In some embodiments, the administration causes killing of the cell or pathogen. In some embodiments, the administration causes inactivation of the cell or pathogen.

[0033] In some embodiments, the subject is a subject with or at risk of a viral infection. In some embodiments, the subject is a subject with or at risk of developing cancer. In some embodiments, the cancer is a metastatic cancer. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a human neonate, infant, adult, or elderly human. In some embodiments, the subject is a companion animal, research animal, or domesticated animal.

[0034] In some embodiments, the administration is intravenous, intramuscular, intradermal, subcutaneous, or by inhalation. In some embodiments, the administration occurs more than once. In some embodiments, the administration is prophylactic administration.

[0035] In another aspect, the present disclosure provides a method for treating a disease in a subject in need thereof or reducing the risk of the subject having a disease, the method comprising administering to the subject an effective amount of any one of the conjugates or compositions described herein. In some embodiments, the disease is caused by a virus, bacteria, parasite, fungus, or cancer.

[0036] In some embodiments, the virus is an influenza virus, a coronavirus, an adenovirus, an enterovirus, a rotavirus, a norovirus, a herpes virus, a lentivirus, a poxvirus, a paramyxovirus, a rhabdovirus, an arenavirus, a flavivirus, a togavirus, a hantavirus, a pneumonia virus, or an Ebola virus. In some embodiments, the virus is an influenza A virus or an influenza B virus. In some embodiments, the virus is a Middle East Respiratory Syndrome Coronavirus (MERS-CoV), a Severe Acute Respiratory Syndrome (SARS)-associated coronavirus (SARS-CoV)-1, or SARS-CoV-2. In some embodiments, the virus is a human immunodeficiency virus (HIV). In some embodiments, the virus is a human respiratory syncytial virus (RSV).

[0037] In some embodiments, the bacterium is Pasteurella, Staphylococcus, Streptococcus, Bacillus, Corynebacterium, Diphtheroids, Listeria, Erysipelothrix, Clostridium, Neisseria, Branhamella, Escherichia, Enterobacter, Proteus, Pseudomonas, Klebsiella, Salmonella, Shigella, Serratia, Acinetobacter, Haemophilus, Brucella, Yersinia, Francisella, Pasteurella, Vibrio cholerae, Flavobacterium, Pseudomonas, Campylobacter, Bacteroides, Fusobacterium, Scabiei, Streptobacillus, or Legionella.

[0038] In some embodiments, the parasite is a Plasmodium, a Trypanosoma, a Toxoplasma, a Leishmania, or a Cryptosporidium. In some embodiments, the parasite is a Plasmodium falciparum, a Plasmodium malariae, a Plasmodium vivax, a Plasmodium knowlesi, a Plasmodium ovale subspecies coryzae, or a Plasmodium ovale subspecies wolleri.

[0039] In some embodiments, the cancer is a blood cancer, lung cancer, breast cancer, brain cancer, gastrointestinal cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, ovarian cancer, testicular cancer, prostate cancer, endometrial cancer, muscle cancer, bone cancer, neuroendocrine cancer, connective tissue cancer, head and neck cancer, or skin cancer. In some embodiments, the cancer is a metastatic cancer.

[0040] In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a human neonate, human infant, adult, or elderly. In some embodiments, the subject is a companion animal, research animal, or domesticated animal.

[0041] In some embodiments, the administration is intravenous, intramuscular, intradermal, subcutaneous, or by inhalation. In some embodiments, the administration occurs more than once. In some embodiments, the administration is prophylactic administration.

[0042] Other aspects of the present disclosure provide antibodies comprising CDR-H1, CDR-H2, and CDR-H3 of any of the antibodies listed in Table 1. In some embodiments, the antibody comprises an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, or at least 99%) identical to any of SEQ ID NOs: 6-17. In some embodiments, the antibody comprises the amino acid sequence of any of SEQ ID NOs: 6-17.

[0043] Other aspects of the present disclosure provide antibodies comprising CDR-H1, CDR-H2, and CDR-H3 of any one of the antibodies listed in Table 2. In some embodiments, the antibody comprises an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, or at least 99%) identical to any one of SEQ ID NOs: 19-27. In some embodiments, the antibody comprises the amino acid sequence of any one of SEQ ID NOs: 19-27.

[0044] The above summary of the invention is intended to illustrate some embodiments, advantages, features and uses of the technology disclosed herein in a non-limiting manner. Other embodiments, advantages, features and uses of the technology disclosed herein will become apparent through the detailed description, drawings, examples and claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] The accompanying drawings are not intended to be drawn to scale. In the drawings, each identical or nearly identical component illustrated in various figures is represented by a like numeral. For clarity, not every component may be labeled in every drawing. In the drawings:

[0046] Figure 1A : Schematic diagram depicting the mechanism by which Nanobody-drug adducts enhance a subject's immunity to cells and / or pathogens. Nanobody-drug adducts comprise antibody fragments (e.g., VHHs) with sufficient affinity to bind to the kappa light chains of host immunoglobulins. κ ), which in turn interact with Fc receptors on host immune cells. At the same time, the Nanobody-drug adduct contains an agent (e.g., zanamivir) sufficient to bind to the surface of target cells and / or pathogens (e.g., cells infected by pathogens, e.g., cells infected by influenza virus) to cause the cells and / or pathogens to be inactivated and / or killed by host immune cells.

[0047] Figure 1B :VHH targeting viral neuraminidase κ - Schematic representation of the mode of action of zanamivir adducts and VHHκ-SD36 adducts targeting viral hemagglutinin.κ The conjugation of zanamivir and SD36 prolongs the circulation half-life of zanamivir and SD36 and enables them to kill virus-infected cells by attracting immune effectors.

[0048] Figure 1C :VHH κ - Zanamivir and VHH κ -Structure of SD36. VHH κ - Zanamivir is synthesized by sortase-mediated triglycine-modified zanamivir and VHH κ VHH κ -SD36 is expressed as a genetically fused heterobivalent Nanobody with a C-terminal sortase recognition motif (LPETG).

[0049] Figure 2 :VHH κ Binds to mouse IgG with nanomolar affinity. VHHs were evaluated using ELISA plates coated with mouse IgG2b. κ Affinity of biotin constructs. HRP-conjugated streptavidin was used as a secondary reagent for detection. SD36 is a nanobody that recognizes influenza hemagglutinin (HA). Affinity is reported as the dissociation constant (K d ). The binding of each construct is depicted by color-coded symbols.

[0050] Figures 3A-3C : Schematic diagram depicting the synthetic steps of Nanobody-drug adduct containing Gly-Gly-Gly-zanamivir. Figure 3A : Schematic diagram depicting the synthesis of zanamivir-targeting ligands from zanamivir. Figure 3B :Depicted by Gly-Gly-Gly-DBCO and Figure 3A Schematic diagram of the synthesis of Gly-Gly-Gly-Zanamivir-targeting ligand depicted in FIG. Figure 3C :Depict VHH κ Tethered to Gly-Gly-Gly-Zanamivir via a sortase reaction (e.g., SrtA) to generate VHHs κ -Schematic diagram of the zanamivir nanobody-drug adduct.

[0051] Figure 4A and 4B :like Figures 3A-3C Depicted synthetic VHH κ -Evaluation of zanamivir nanobody-drug adducts. Figure 4A : 15% reducing SDS-PAGE showed VHH κ - Zanamivir is primarily synthesized as a single product with a molecular weight of approximately 14 kDa. Figure 4B .VHHκ -The mass spectrum of zanamivir showed that Figures 3A-3C The synthetic VHHs depicted in κ - Purity of zanamivir.

[0052] Figures 5A-5D :VHH κ -Zanamivir binds to influenza neuraminidase with nanomolar affinity. Figure 5A Madin-Darby canine kidney (MDCK) cells were infected with influenza A virus A / Wisconsin / 629-D00015 / 2009 (H1N1) and expressed influenza A neuraminidase within 24 hours after infection. κ -zanamivir nanobody-drug adducts were used to treat infected cells. VHHs were evaluated by saturation binding assay κ - Affinity of zanamivir for cell surface-localized influenza A neuraminidase. Mouse IgG-phycoerythrin (PE) was used as a secondary antibody to evaluate VHH κ -Zanamivir affinity. VHH κ -The nanomolar affinity of zanamivir for influenza A neuraminidase was determined from logarithmic regression of observed binding and reported as the dissociation constant (K d ). Figure 5B :like Figure 5A VHH κ - The affinity of zanamivir for influenza A neuraminidase was assessed, however, MDCK cells were instead infected with influenza A virus A / Hong Kong / 8 / 1968(H3N2). κ -The nanomolar affinity of zanamivir for influenza A neuraminidase was determined from logarithmic regression of observed binding and reported as the dissociation constant (K d ). Figure 5C Madin-Darby canine kidney (MDCK) cells were infected with influenza B virus B / Florida / 4 / 2006 and expressed influenza B neuraminidase within 24 hours after infection. κ -zanamivir nanobody-drug adducts were used to treat infected cells. VHHs were evaluated by saturation binding assay κ - Affinity of zanamivir for cell surface-localized influenza B neuraminidase. Mouse IgG-phycoerythrin (PE) was used as a secondary antibody to evaluate VHH κ -Zanamivir affinity. VHH κ - The nanomolar affinity of zanamivir for influenza B neuraminidase was determined from logarithmic regression of observed binding and reported as the dissociation constant (K d ). Figure 5D:like Figure 5A VHH κ - The affinity of zanamivir for influenza B neuraminidase was assessed, however MDCK cells were instead infected with influenza B virus B / Brisbane / 60 / 2008. κ - The nanomolar affinity of zanamivir for influenza B neuraminidase was determined from logarithmic regression of observed binding and reported as the dissociation constant (K d ).

[0053] Figures 6A-6E : Single intraperitoneal injection of VHH κ -Zanamivir protects mice from lethal influenza infection. Figure 6A : On day 0, 50 mL of influenza A virus / Puerto Rico / 8 / 1934(H1N1) (10LD 50 ) infected mice. Mice received intraperitoneal PBS control, a single dose of VHH on day 0 after infection. κ - Zanamivir or its components, or VHH administered intraperitoneally at doses on days 0, 2, and 4 post-infection κ - Zanamivir. The infected mice were monitored daily for percentage change in body weight for up to 14 days post infection. κ - Treatment of mice with zanamivir or its components. Figure 6B :Infected mice such as Figure 6A Treatments were performed and survival was monitored daily for up to 14 days post infection. κ - Mice treated with zanamivir or higher doses showed no influenza lethality within 14 days after infection. κ - Treatment of mice with zanamivir or its components. Figure 6C :Infected mice such as Figure 6A Treatments were performed and survival was monitored daily for up to 14 days post-infection. κ - Efficacy of zanamivir against different strains of the indicated influenza viruses. Figure 6D : Delayed addition of VHHs on day 1, 2, or 3 post-infection κ -Zanamivir. Figure 6E : Seven days after adding a single dose of VHHκ-zanamivir, mice were infected with influenza A / Puerto Rico / 8 / 1934 (H1N1).

[0054] Figures 7A-7E : Synthesis of SD36-VHHκ adducts via copper-free click reaction. Figure 7A: Synthesis of SD36-azide, sortase A catalyzes the addition of a tri-glycine-azide-lysine peptide to the C-terminus of SD36. Figure 7B :VHH κ -DBCO synthesis, sortase A catalyzes the addition of tri-glycine DBCO-functionalized cysteine ​​peptides to anti-mouse VHH κ C-terminus. Figure 7C : SD36-azide reacts with VHH via a copper-free click reaction κ -DBCO conjugation. Figure 7D : Gene fusion anti-mouse VHH κ -Schematic diagram of SD36. Figure 7E : 15% reducing SDS-PAGE showed VHH κ -SD36 is mainly synthesized as a single product with a molecular weight of approximately 30 kDa. κ - Mass spectrometry of SD36 indicated purity.

[0055] Figures 8A-8C :VHH κ -Biotin, VHH κ -Synthesis of SD36-biotin and SD36-biotin. Figure 8A : Sortase A catalyzes the addition of tri-glycine-biotin-functionalized cysteine ​​peptides to anti-mouse VHH κ C-terminus. Figure 8B : Sortase A catalyzes the addition of a tri-glycine-biotin-functionalized cysteine ​​peptide to a genetically fused anti-mouse VHH κ -C-terminus of the SD36 conjugate. Figure 8C : Sortase A catalyzes the addition of a tri-glycine-biotin-functionalized cysteine ​​peptide to the C-terminus of SD36.

[0056] Figures 9A-9C :SD36 and VHH κ - Binding affinity of SD36 to various influenza virus hemagglutinins. Figure 9A : Saturation binding curve of SD36-biotin to hemagglutinin (HA) expressed on MDCK cells infected with influenza virus. Streptavidin-phycoerythrin (PE) was used to quantify the amount of SD36-biotin bound to HA. Figure 9B : Anti-mouse VHH κ - Saturation binding curve of SD36-biotin (gene fusion) to hemagglutinin (HA) expressed on influenza virus-infected MDCK cells. Streptavidin-phycoerythrin (PE) was used to quantify anti-mouse VHH binding to HA. κ -Amount of SD36-biotin. Figure 9C : Anti-mouse VHH κ- Saturation binding curve of SD36 (CC conjugated by click reaction) to hemagglutinin (HA) expressed on influenza virus infected MDCK cells. Mouse IgG-phycoerythrin (PE) was used to quantify the binding of anti-mouse VHH to HA. κ -The amount of SD36. Data are presented as mean ± SD (n = 3).

[0057] Figures 10A-10C : Single intraperitoneal injection of VHH κ -SD36 protected against lethal influenza virus infection. 50 μL of influenza A virus / Puerto Rico / 8 / 1934 (H1N1) (=10 LD 50 ) Intranasally infected mice. Mice received a single dose of anti-mouse VHH intraperitoneally on the day of infection. κ -SD36 gene fusion ( Figure 10A ) or anti-mouse VHH κ -SD36 (CC conjugation via click reaction, Figure 10B ). Figure 10C , delayed addition of VHH 1, 2, or 3 days after infection κ -SD36. For the survival curve, mice that lost more than 25% of their initial body weight or mice that were moribund were considered dead. The weight change curve (left) and survival curve (right) for each treatment are shown. The weight change values ​​(%) are presented as mean ± SD.

[0058] Figure 11A and 11B :SD36-DFO( 89 Zr-chelated) and VHHκ-SD36-DFO ( 89 Preparation of Zr chelated). Figure 11A : Sortase A catalyzes the addition of the triglycine deferoxamine (DFO) peptide to the C-terminus of SD36. Zirconium-89 ( 89 Zr) forms a chelate with DFO. Figure 11B : Sortase A catalyzes the addition of a triglycine-deferoxamine (DFO) peptide to the C-terminus of an anti-mouse VHHκ-SD36 conjugate. Zirconium-89 ( 89 Zr) forms a chelate with DFO.

[0059] Figure 12 : Using VHH κ -SD36-DFO( 89 Zr chelated) and SD36-DFO ( 89 ImmunoPET imaging of influenza virus infection with Zr-chelated 50 μL of influenza A virus / Hong Kong / 8 / 1968 (H3N2) (=10 LD 50) were intranasally infected with mice. On day 4 after infection, a single dose of 60 μCi of SD36-DFO ( 89 Zr-chelated) or anti-mouse VHH κ -SD36-DFO( 89 Mice were injected retro-orbitally with a Zr-chelated PET. Mice were scanned using a PET scanner for 10 minutes. Images were processed using Vivoquant using the same intensity settings. Images were taken at different time points after injection of the imaging agent. Images taken 48 hours after injection of the imaging agent were partially magnified to examine details of viral infection in the mouse chest.

[0060] Figures 13A-13D : VHH nanoantibodies specifically bind to Plasmodium falciparum merozoite surface protein 1 (MSP-1). Figure 13A : Schematic diagram of the PfMSP-1 propeptide and its four internal subunits p83, p30, p38, and p42. Figure 13B Purified anti-p84B4, anti-p38B8, anti-p42A6 and anti-p42G11 VHHs were biotinylated and incubated with plate-bound subunit proteins as indicated. Binding was detected by ELISA using streptavidin-HRP and tetramethylbenzidine (TMB). Data are expressed as optical density (OD). Error bars show SEM. Figure 13C : Western blot of VHH against the three PfMSP-1 subunits, the full-length p190 propeptide, and some 3D7 lysates from approximately 38-44 hour old 3D7 merozoites. Figure 13D : Flow cytometry of approximately 38-44 hour synchronized 3D7 merozoites using fluorescent (Cy5) labeled VHHs.

[0061] Figures 14A-14C : Synthesis of VHHs via a copper-free click reaction κ -VHH7 adduct. Figure 14A : Synthesis of VHH7-azide, sortase A catalyzes the addition of a tri-glycine-azide-lysine peptide to the C-terminus of VHH7. Figure 14B :VHH κ -DBCO synthesis, sortase A catalyzes the addition of a tri-glycine DBCO-functionalized cystine peptide to the anti-mouse VHH κ C-terminus. Figure 14C : VHH7-azide reacts with VHH via a copper-free click reaction κ -DBCO conjugation.

[0062] Figure 14D :Use 10LD 50 Female BALB / c mice aged 6 to 9 weeks were infected with influenza virus. κ -SD36, VHHκ The mixture of SD36 and PBS or an equal volume of PBS was injected into the peritoneum to treat mice. When the mice lost 25% of their body weight or were dying, they were euthanized. Shown are weight loss curves (left) and survival rate curves (right). For weight loss curves, weight change (%) values ​​represent mean ± standard deviation. Utilization uses the one-way ANOVA analysis using Tukey's multiple comparisons test (Tukey's multiple comparisons test) to compare the mean value of weight change % of any two groups within 14 days, and shows the statistical difference (*P<0.05, **P<0.01, ***P<0.001, referring to all comparisons and P values ​​in Table S1) between the specified group and the PBS-treated group. For survival rate curves, the statistical difference (*P<0.05, **P<0.01) between the specified group and the PBS-treated group was calculated by log-rank (Mantel-Cox) test.

[0063] Figure 15A and 15B :VHH κ -VHH7 adduct-induced complement-dependent cytotoxicity (CDC) in A20 cells. Figure 15A : Schematic diagram showing the experimental procedure of complement-dependent cytotoxicity assay. Figure 15B : Bar graph showing the percentage of VHH-induced cytotoxicity. Error bars represent standard deviation (n=4).

[0064] Figure 16A and 16B :VHH κ - Antibody-dependent cellular cytotoxicity (ADCC) of A20 cells induced by VHH7 adducts. Figure 16A : Schematic diagram showing the experimental procedure of antibody-dependent cellular cytotoxicity assay. Figure 16B : Bar graph showing the percentage of total cell lysis induced by VHHs. Error bars represent standard deviation (n=3).

[0065] Figures 17A-17E : Development of MHC class I peptide-related sequence A (MICA)-specific nanobodies. Figure 17A : Comparison of the amino acid sequences of nine MICA-specific Nanobodies that have been identified and cloned into the pHen6 expression vector. Figure 17B : Immunoblot showing specific binding of biotinylated A1 and H3 anti-MICA Nanobody clones to purified MICA*009 antigen in whole cell lysates. Figure 17C: Quantification of ELISA cross-competition assay for determining the binding epitope of anti-MICA nanobodies. Compared only to single nanobodies, the reduction in intensity measured at 450 nm indicates that it binds to the same epitope. Cross-competition of A1 (left) and H3 (right) anti-MICA nanobody clones is shown. Figure 17D : Quantification of anti-MICA Nanobodies binding to MICA allele products as determined by ELISA. A significant increase in the intensity measured at 450 nm compared to the uncoated ELISA control indicates binding. Figure 17E : Flow cytometry of B16F10 cells transfected with empty vector, MICA or MHC class I polypeptide-related sequence B (MICB) using A1 and H3 anti-MICA Nanobody clones.

[0066] Figures 18A-18C :VHH κ -Biotin and VHH κ -Affinity of SD36-biotin for mouse immunoglobulins. Figure 18A :VHH κ -Biotin and VHH κ -Saturation binding curve of SD36-biotin to mouse polyclonal IgG. Figure 18B :VHH κ -Biotin and VHH κ -Saturation binding curve of SD36-biotin to monoclonal mouse IgM. Figure 18C :VHH κ -Biotin and VHH κ - Saturation binding curve of SD36-biotin to mouse polyclonal IgA coated on ELISA plates. The amount of VHH bound to mouse immunoglobulins was quantified using streptavidin-phycoerythrin (PE).

[0067] Figures 19A-19B : Neuraminidase inhibition assay. VHH κ -Zanamivir, ALB1-Zanamivir, Zanamivir and VHH κ Neuraminidase inhibitory activity of NA-Star TM Influenza Neuraminidase Inhibitor Resistance Detection Kit measures the neuraminidase resistance of various influenza strains as the source of neuraminidase. Figure 19A : Summary of the half maximal inhibitory concentration (IC50) values ​​of the tested molecules. Figure 19B : Dose inhibition curves of the tested molecules.

[0068] Figures 20A-20B :VHH κ- Saturation binding curve of SD36 to hemagglutinin expressed on influenza virus-infected MDCK cells. Quantification of VHH binding to hemagglutinin using mouse IgG-phycoerythrin (PE) κ -Amount of SD36. Data represent mean ± standard deviation (n=3).

[0069] Figure 21 :VHH κ -Zanamivir, MEDI8852 and VHH κ -E11. Comparison of therapeutic efficacy between 10LD 50 Female BALB / c mice aged 6 to 9 weeks were infected with influenza virus. κ - Zanamivir, MEDI8852, or VHH κ -E11 (SARS CoV-2 spike-specific nanoantibodies) were injected intraperitoneally into mice. When the mice lost 25% of their body weight or were dying, they were euthanized. Shown are weight loss curves (left) and survival curves (right). For weight loss curves, % body weight change represents mean ± standard deviation. The mean value of % body weight change in any two groups over 14 days was compared using a one-way ANOVA analysis using Tukey's multiple comparison test. Shown are the statistical differences between the specified group and the PBS-treated group (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001). For survival curves, the statistical differences between the specified group and the PBS-treated group (*P<0.05, **P<0.01) were calculated by log-rank (Mantel-Cox) test.

[0070] Figures 22A-22B : SD36-DFO and VHH for PET imaging κ -Preparation of SD36-DFO. Figure 22A : Nanobody-DFO adducts were prepared by sortase-mediated conjugation of triglycine-modified DFO to Nanobody. Figure 22B : Analysis of SD36-DFO (left) and VHH by SDS-PAGE κ -The final product of SD36-DFO (right).

[0071] Figures 23A-23E :VHH κ - Zanamivir induces CDC and ADCC. Figure 23A In the presence of rabbit complement and mouse polyclonal mouse IgG, influenza virus-infected MDCK cells were infected with VHH κ -zanamivir killing. VHH was analyzed by t-test κ- Difference in % cytotoxicity between the zanamivir-treated group and the group treated with individual components as a mixture (data represent mean ± standard deviation, n=5, *P<0.05, **P<0.01, ***P<0.001). Figure 23B : In the presence of VHH κ In the presence of zanamivir and mouse polyclonal mouse IgG, virus-infected MDCK cells induced luciferase expression in luciferase-expressing reporter cells with the involvement of the mouse FcγRIV receptor. ADCC induction was calculated by dividing the luminescence intensity of the designated sample by the mean of the control sample containing virus-infected cells and reporter cells without VHH. VHH expression was analyzed by t-test. κ - Difference in fold induction between the zanamivir-treated group and the group treated with a mixture of individual components (data represent mean ± SD, n = 5, *P < 0.05, **P < 0.01, ***P < 0.001). These results represent at least two independent experiments for CDC and ADCC assays. Figure 23C : Weight loss curve (left) and survival curve (right) for comparison of VHH κ -Efficacy between zanamivir and ALB1-zanamivir. Figure 23D : Retroorbital injection of nanobodies 89 Measurement of Nanobody Clearance After Zr-labeled Constructs. For each blood draw time point after the initial injection of the construct (x-axis: 10 min, 1 h, 24 h, 48 h, 72 h, 96 h, and 144 h), the number of counts per minute (CPM) of 10 μL whole blood (y-axis) was calculated. 89 Each individual measurement of the Zr decay rate is shown as a blue square (VHH κ -DFO- 89 Zr, n=3)、red circle (ALB1-DFO- 89 Zr, n = 4) or black triangle (SD36-DFO- 89 Zr, n=3). All mice received an initial dose of 250 μCi 89 Zr-labeled VHH (equal to 1 mg / kg VHH). Each data point represents the mean ± standard deviation. A two-phase decay model was used to estimate the half-life of each VHH (rapid phase and slow phase). Total VHH exposure in the first 144 hours after injection was calculated by integrating the VHH concentration in the blood over time. This is expressed as the 'area under the curve' (AUC). Figure 23E : Receive anti-mouse VHH κ -The weight loss curve (left) and survival rate curve (right) of Rag1 knockout mice infected with the virus of zanamivir plus mouse polyclonal IgG. Figure 23C and Figure 23E ,exist Figure 23C The body weight change percentages are shown as mean ± standard deviation, and the body weight change curves of individual mice are shown in Figure 23E The mean values ​​of the weight changes of % in any two groups over 14 days were compared using one-way ANOVA analysis using Tukey's multiple comparison test. The statistical differences between the specified group and the group treated with PBS (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001) are shown. For survival rate curves, the statistical differences between the specified group and the group treated with PBS (*P < 0.05, **P < 0.01) were calculated by log-rank (Mantel-Cox) test.

[0072] Figure 24A and 24B :VHH κ -SD36 induces ADCC but not CDC. Figure 24A : In the presence of VHH κ In the case of VHH-SD36 and mouse polyclonal mouse IgG, virus-infected MDCK cells induced luciferase expression in luciferase-expressing reporter cells with the participation of the mouse FcγRIV receptor. The fold induction was calculated by dividing the luminescence intensity of the indicated samples by the mean of the control samples containing virus-infected cells and reporter cells without VHH. The expression of VHHs was analyzed by t-test. κ - Difference in fold induction between the SD36-treated group and the group treated with a mixture of individual components (data represent mean ± standard deviation, n=5, *P<0.05, **P<0.01, ***P<0.001). Figure 24B : In the presence of rabbit complement and polyclonal mouse IgG, VHH κ -SD36 did not significantly kill MDCK cells infected with influenza virus. κ - Difference in % cytotoxicity between the SD36-treated group and the group treated with individual components as a mixture (data represent mean ± standard deviation, n=5, *P<0.05, **P<0.01, ***P<0.001). These results represent at least two independent experiments for ADCC and CDC assays.

[0073] Figure 25A and 25B : Preparation of ALB1-zanamivir. Figure 25A : Amino acid sequence of anti-serum albumin nanobody (ALB1). The sortase recognition motif (LPETG) is linked to the C-terminus of the nanobody. Figure 25B: ALB1-zanamivir was prepared by sortase-mediated conjugation of triglycine-modified zanamivir to ALB1. The identity of the final product ALB1-zanamivir was confirmed by SDS-PAGE (left) and mass spectrometry (right).

[0074] Figure 26 : VHH for PET imaging κ Preparation of ALB1-DFO, ALB1-DFO and SD36-DFO. Nanobody-DFO adducts were prepared by sortase-mediated conjugation of triglycine-modified DFO to Nanobody. Nanobody-DFO adducts were analyzed by SDS-PAGE (for each gel, in order from left to right: 1: sortase, 2: unconjugated Nanobody, 3: reaction mixture, 4-9: different fractions obtained after elution from the PD-10 column, Nanobody-DFO adduct shown as #6 on the gel was used for PET imaging). DETAILED DESCRIPTION

[0075] Some aspects of the present disclosure are based, at least in part, on the discovery that conjugate molecules that specifically bind to both an antigen located on the surface of a cell or pathogen and a structural feature shared with many different immunoglobulins produced in the host (e.g., kappa or lambda light chain sequences) can be used to recruit immune cells with cell surface Fc receptors to cells or pathogens expressing the antigen, regardless of the clonality or specificity of the host immunoglobulins. As described herein, these conjugates can be used to enhance or elicit an immune response in a subject to a specific virus or cell. This approach can be used to treat a disease associated with the targeted virus or cell in a subject or to reduce the risk of developing the disease. In some embodiments, the conjugates described herein can be used to treat (both prophylactically and therapeutically) one or more diseases in a subject, including infections caused by pathogens (e.g., viruses, bacteria, parasites, fungi) and cancers. As further described, the disclosed conjugates can also be used to ablate specific types of cells in a subject, whether or not the cells are associated with the disease.

[0076] Conjugate

[0077] Without wishing to be bound by theory, during the innate (cell-mediated) immune response, a variety of immune cell types directly target potential pathogens or harmful cells, causing these cells to be killed or inactivated (i.e., preventing them from breeding). In this way, immune cells, such as macrophages, dendritic cells, natural killer cells, neutrophils, basophils, eosinophils and mast cells contain and destroy pathogenic infections and cancers that occur in their hosts. However, these immune cells are generally unable to directly interact with their targets because their surfaces lack the receptors required for this interaction. On the contrary, many immune cells express receptor proteins referred to as crystallizable fragment (Fc) receptors on their surfaces. Fc receptors can bind to the host immunoglobulins of the object, and each immunoglobulin has specificity for a particular antigen. When the immunoglobulin bound by Fc receptors binds to its target antigen (such as an antigen that appears on the surface of a pathogen or other target cell), it brings the target to a place close enough to the immune cell, causing the pathogen or other target cell to be killed or inactivated.

[0078] Although this system allows for the protection of a wide range of possible targets, the efficacy of many immune cells is largely based on the amount of immunoglobulins that are specific for specific antigens in the subject's body. In other words, if the amount of immunoglobulins that are specific for the antigens on the surface of pathogens or cancer cells is insufficient, the ability of certain immune cell types to produce effective responses will be limited. Fortunately, by providing molecules that can enhance the proximity of Fc receptor-positive immune cells to their targets, the immune response in the subject's body can be enhanced or triggered. This paper provides such molecules, which are conjugates between a first agent that is specific for the immunoglobulins produced by the host and a second agent that is specific for the antigens on the surface of cells or pathogens. By selecting a first agent that specifically binds to a structural feature (such as κ light chain or λ light chain) shared with many host immunoglobulins, these conjugates can be combined with the target and the immunoglobulin bound to the Fc receptor-positive immune cell at the same time. By effectively bridging immune cells and their targets, these conjugates can enhance immunity to almost any potential target only by customizing the target specificity of the second agent, without relying on the specificity of the host immunoglobulin.

[0079] Thus, some aspects of the present disclosure describe a conjugate comprising a first agent that binds to an immunoglobulin and a second agent that binds to a target on the surface of a cell or pathogen, wherein the first agent and the second agent are covalently conjugated via a linker. In some embodiments, the first agent specifically binds to the immunoglobulin. In some embodiments, the second agent specifically binds to a target on the surface of a cell or pathogen.

[0080] In some embodiments, the first agent is an antibody or an antibody fragment thereof (e.g., a recombinant antibody fragment, such as, but not limited to, a fragment antigen binding (Fab) fragment, a single-chain variable fragment (ScFv), or a single domain antibody (sdAb)). In some embodiments, the first agent is a single domain antibody, which is alternatively referred to as a "nanobody" in the art. In some embodiments, the first agent is a single domain antibody (being a heavy chain antibody), i.e., a single domain antibody fragment derived from an immunoglobulin containing only a heavy chain, such as those commonly found in mammalian species belonging to the family Camelidae. Such fragments are referred to in the art as "VHHs," which are recombinantly expressed as "nanobodies." In some embodiments, the first agent is a recombinant single domain antibody, such as a recombinant VHH or a nanobody.

[0081] The first agent of the conjugate described herein is combined with an immunoglobulin. "Immunoglobulin" refers to an antibody protein complex produced and secreted by lymphocytes or plasma cells. An immunoglobulin generally comprises one or more heavy chains and one or more light chains, and the one or more heavy chains and one or more light chains are covalently linked to each other by disulfide bonds. The heavy and light chains of an immunoglobulin can each comprise a variable region and a constant region, and the variable region comprises an amino acid sequence that differs between immunoglobulin clones and determines which antigen is bound to the immunoglobulin (e.g., heavy chain variable region and light chain variable region), and the constant region is constant between antibody clones (e.g., heavy chain constant region and light chain constant region). Depending on its total mass and the number of antigen binding sites, an immunoglobulin can belong to any one of several structural categories (isotypes). For example, an immunoglobulin can be immunoglobulin A (IgA), immunoglobulin D (IgD), immunoglobulin E (IgE), immunoglobulin G (IgG), or immunoglobulin M (IgM). Immunoglobulins can further belong to specific structural subclasses, such as IgG subclass 1 (IgG1), IgG subclass 2 (IgG2), IgG subclass 3 (IgG3) and IgG subclass 4 (IgG4). The class and subclass of immunoglobulins determine many functional properties of immunoglobulins, such as, but not limited to, their biodistribution. In some embodiments, the immunoglobulins described herein comprise heavy chains containing a crystallizable fragment (Fc) region. The Fc region is comprised by the heavy chain constant region and is necessary for binding to Fc receptors (such as Fc receptors on the surface of immune cells (e.g., macrophages, dendritic cells, natural killer cells, neutrophils, basophils, eosinophils, mast cells). All circulating immunoglobulins comprise an Fc region.

[0082] The present disclosure specifically relates to immunoglobulins comprising light chains that are either kappa (kappa) or lambda (lambda) light chains. Kappa and lambda light chains are expressed by genes within different genetic loci, referred to as IGK (NCBI gene ID: 50802) and IGL (NCBI gene ID: 3535), respectively, which are located on different chromosomes (e.g., in humans, IGK is located on chromosome 2 and IGL is located on chromosome 22). In some embodiments, the immunoglobulins of the present disclosure comprise kappa light chains expressed by the IGK locus. In some embodiments, the immunoglobulins of the present disclosure comprise lambda light chains expressed by the IGL locus.

[0083] In some embodiments, the first agent binds to an immunoglobulin kappa light chain or an immunoglobulin lambda light chain. In some embodiments, the first agent is a nanobody or a single domain antibody (e.g., VHH) that binds to an immunoglobulin kappa light chain or an immunoglobulin lambda light chain. In some embodiments, the first agent is a nanobody or a single domain antibody (e.g., VHH) that binds to an immunoglobulin kappa light chain or an immunoglobulin lambda light chain of a specific species (e.g., human). In some embodiments, the first agent is a nanobody or a single domain antibody (e.g., VHH) that specifically binds to an immunoglobulin kappa light chain (e.g., human immunoglobulin kappa light chain). As used herein, a nanobody or a single domain antibody that is VHH and has specificity for a kappa light chain is referred to as a "VHH κ ”. Exemplary VHH κ The amino acid sequence is as follows:

[0084] Anti-mouse IgGκ light chain VHH:

[0085] QVQLVESGGGWVQPGGSLRLSCAASGFTFSDTAMMWVRQAPGKGREWVAAIDTGGGYTYYADSVKGRFTISRDNAKNTLYLQMNSLKPEDTARYYCAKTYSGNYYSNYTVANYGTTGRGTLVTVSSGG(SEQ ID NO:1)

[0086] Anti-human IgGκ light chain VHH:

[0087] QVQLQESGGGLVQPGGSLRLSCAASGRTISRYAMSWFRQAPGKEREFVAVARRSGDGAFYADSVQGRFTVSRDDAKNTVYLQMNSLKPENTAVYYCAIDSDTFYSGSYDYWGQGTQVTVSSGG(SEQ ID NO:2)

[0088] In some embodiments, the second agent comprises a small molecule, a peptide, a protein, a carbohydrate, a lipid, a nucleotide, a nucleic acid, an oligonucleotide, an aptamer, or an antibody or an antibody fragment thereof (e.g., a fragment antigen binding (Fab) fragment, a single chain variable fragment (ScFv) or a nanobody or a single domain antibody (sdAb)). In some embodiments, the second agent is a small molecule, a peptide, a protein, a carbohydrate, a lipid, a nucleotide, a nucleic acid, an oligonucleotide, an aptamer, or an antibody or an antibody fragment thereof (e.g., a fragment antigen binding (Fab) fragment, a single chain variable fragment (ScFv) or a nanobody or a single domain antibody (sdAb)). In some embodiments, the second agent is a small molecule (e.g., a small molecule inhibitor). In some embodiments, the second agent is an antibody or an antibody fragment thereof. In some embodiments, the second agent is a single domain antibody. In some embodiments, the second agent has a therapeutic effect when administered to a subject (e.g., the second agent is administered alone to a subject). In some embodiments, the second agent does not have a therapeutic effect when administered to a subject (e.g., the second agent is administered alone to a subject). In some embodiments, the second agent specifically binds to a target on the surface of a cell or pathogen of a particular species (e.g., a target on the surface of a particular virus, bacteria, parasite, fungus, or human cell (such as a cancer cell)) or a target across a range of related species (e.g., where the species express substantially similar versions of the target on their surface).

[0089] In some embodiments, the first agent and the second agent are covalently linked via a linker. In some embodiments, the linker comprises a cleavable linker or a non-cleavable linker. A "cleavable linker" refers to a linker in which one or more covalent bonds are cleaved (broken) under certain conditions (such as conditions under which cleavage (fracture) occurs in a cell or object). A "non-cleavable" linker refers to a linker that cannot be effectively or reliably cleaved under certain conditions (such as conditions under which cleavage (fracture) occurs in a cell or object) for all intents and purposes. Examples of cleavable linkers familiar to those skilled in the art include peptide linkers (e.g., Val-Cit), disulfide linkers, and hydrazone linkers, which are cleaved by proteolysis, reduction, and low pH, respectively. Examples of non-cleavable linkers include, for example, N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) and polyethylene glycol (PEG). Additional examples of linkers known in the art include, for example, the linkers in Lu et al., "Linkers Having a Crucial Role in Antibody-Drug Conjugates," Int J Mol Sci, 17(4), 561., the contents of which are incorporated herein by reference.

[0090] In some embodiments, the linker is a triglycine dibenzylcyclooctyne (DBCO) linker as follows:

[0091]

[0092] In some embodiments, the second agent is a protein or peptide (e.g., an antibody or an antibody fragment thereof (e.g., a fragment antigen binding (Fab) fragment, a single chain variable fragment (ScFv) or a nanobody or a single domain antibody (sdAb)), and the linker is a peptide bond, an isopeptide bond, or a disulfide bond. In some embodiments, the linker comprises one or more amino acids that connect the first agent and the second agent, for example, a repeating linker comprising glycine and / or serine, or another amino acid linker generally known in the art. In some embodiments, the first agent and the second agent are translated separately (e.g., translated in an in vitro translation system or recombinantly expressed in a cell) and post-translationally linked. In some embodiments, the first agent and the second agent are translated as a fusion protein (e.g., in an in vitro translation system or recombinantly expressed in a cell), wherein the first agent and the second agent are linked by one or more peptide bonds. In some embodiments, the first agent and the second agent are expressed by inserting one or more nucleic acids (e.g., DNA or RNA) encoding the first agent and the second agent into the fusion protein. In some embodiments, the first and second agents are encoded by different nucleic acids (e.g., DNA or RNA). In some embodiments, the first and second agents are encoded by the same nucleic acid (e.g., DNA or RNA). In some embodiments, the first and second agents are encoded by one or more plasmids or mRNA and inserted (transfected) into cells by any method known in the art (e.g., electroporation). In some embodiments, the nucleic acids encoding the first and second agents are inserted (transfected) into cells using viral vectors (e.g., adenoviral vectors, lentiviral vectors) by any method known in the art. In some embodiments, the nucleic acids encoding the first and second agents are inserted into cells by chromosomes by any method known in the art.

[0093] In some embodiments, the second agent is linked to the first agent via a sortase (e.g., sortase A). Sortases are a class of enzymes that specifically target the amino acid motif LPXTG, where X is any amino acid, by cleaving the C-terminus of a threonine residue, creating a peptide bond between the threonine and the sortase, which is then transferred to the N-terminus of another protein. In some embodiments, prior to linking to the second agent, the first agent (e.g., VHH κ) is tagged at its C-terminus with a sortase recognition sequence, such as LPETGGHHHHHH (SEQ ID NO: 3). In some embodiments, the second agent is a protein or peptide (e.g., an antibody or an antibody fragment thereof (e.g., a fragment antigen-binding (Fab) fragment, a single-chain variable fragment (ScFv) or a nanobody or a single-domain antibody (sdAb)) that is tagged at its C-terminus with a sortase recognition sequence prior to being linked to the first agent.

[0094] In some embodiments, the second agent specifically binds to a target present on the surface of a specific cell, such as a cell infected with a pathogen (e.g., a virus, bacteria, parasite, fungus), a cancer cell, a transformed cell, a healthy cell, or a cell that is undergoing or has undergone a phenotypic change in response to cellular stress. The cell that is undergoing or has undergone a phenotypic change in response to cellular stress may be a cell that is undergoing or has undergone a phenotypic change in response to cellular stress caused by, but not limited to, oxidative stress, nutritional stress, hypoxia, heat shock, ionizing radiation, exposure to heavy metals, or exposure to mutagens or physical damage.

[0095] In some embodiments, the second agent specifically binds to a target present on the surface of a pathogen (e.g., a pathogenic virus, bacterium, parasite, or fungus). In some embodiments, the pathogen is a virus. In some embodiments, the virus is an influenza virus, a coronavirus, an adenovirus, an enterovirus, a rotavirus, a norovirus, a herpes virus, a lentivirus, a poxvirus, a paramyxovirus, a rhabdovirus, an arenavirus, a flavivirus, a togavirus, a hantavirus, a pneumovirus, or an Ebola virus.

[0096] In some embodiments, the virus is an influenza virus. In some embodiments, the virus is an influenza A virus or an influenza B virus. In some embodiments, the target bound to the second agent is an influenza virus neuraminidase or an influenza virus hemagglutinin, such as an influenza virus neuraminidase or an influenza virus hemagglutinin expressed on the surface of an influenza A virus or an influenza B virus. In some embodiments, the second agent is a small molecule inhibitor, such as a small molecule inhibitor that binds to an influenza virus neuraminidase. In some embodiments, the second agent includes zanamivir, oseltamivir, peramivir, or an analog thereof. In some embodiments, the second agent is an antibody or an antibody fragment thereof (e.g., a fragment antigen binding (Fab) fragment, a single-chain variable fragment (ScFv), or a single domain antibody (sdAb)) that binds to an influenza virus neuraminidase or an influenza virus hemagglutinin. In some embodiments, the second agent is a VHH that binds to an influenza virus hemagglutinin. Examples of VHHs that bind to an influenza virus hemagglutinin are as follows:

[0097] Anti-HAVHH (SD36):

[0098] EVQLVESGGGLVQAGGSLKLSCAASGRTYAMGWFRQAPGKEREFVAHINALGTRTYYSDSVKGRFTISRDDNAKNTEYLEMNNLKPEDTAVYYCTAQGQWRAAPVAVAAEYEFWGQGTQVTVSSGG (SEQ ID NO: 4).

[0099] In some embodiments, the first agent and the second agent are linked via a trisglycine dibenzylcyclooctyne (DBCO) linker. In some embodiments, the first agent and the second agent are linked via a trisglycine dibenzylcyclooctyne (DBCO) linker, and the second agent is zanamivir.

[0100] In some embodiments, the virus is a beta coronavirus. In some embodiments, the beta coronavirus is Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome (SARS)-related Coronavirus (SARS-CoV)-1, or SARS-CoV-2. In some embodiments, the target that the second agent binds to is the MERS-CoV spike protein, the SARS-CoV-1 spike protein, or the SARS-CoV-2 spike protein. In some embodiments, the target that the second agent binds to is the MERS-CoV spike protein receptor binding domain (RBD), the SARS-CoV-1 spike protein RBD, or the SARS-CoV-2 spike protein RBD. In some embodiments, the second agent is an antibody or an antibody fragment thereof (e.g., a fragment antigen binding (Fab) fragment, a single-chain variable fragment (ScFv), or a single domain antibody (sdAb)) that binds to a target on the surface of MERS-CoV, SARS-CoV-1, or SARS-CoV-2 (e.g., a MERS-CoV spike protein, a SARS-CoV-1 spike protein, or a SARS-CoV-2 spike protein, or a MERS-CoV spike protein RBD, a SARS-CoV-1 spike protein RBD, or a SARS-CoV-2 spike protein RBD). In some embodiments, the second agent specifically binds to a target expressed on the surface of SARS-CoV-2. In some embodiments, the second agent specifically binds to a target expressed on the surface of SARS-CoV-2 where it was originally discovered. In some embodiments, the second agent specifically binds to a target expressed on the surface of an identified SARS-CoV-2 variant (such as a variant of interest (VOC) identified by the United States Centers for Disease Control and Prevention (CDC), such as, but not limited to, existing variants B.1.1.7(α), B.1.351(β), P.1(γ), B.1.617.2(δ), B.1.427 and B.1.429(ε), B.1.525(η), B.1.526(ι), B.1.617.1(κ), B.1.1.529(ο), B.1.621(μ) and P.2(ζ) variants, as well as those SARS-CoV-2 variants that have not yet appeared).

[0101] In some embodiments, the virus is a lentivirus. In some embodiments, the lentivirus is human immunodeficiency virus (HIV). In some embodiments, the target bound to the second agent is HIV envelope glycoprotein gp120. In some embodiments, the second agent specifically binds to a target expressed on the surface of HIV. In some embodiments, the second agent is an antibody or an antibody fragment thereof (e.g., a fragment antigen binding (Fab) fragment, a single-chain variable fragment (ScFv) or a single domain antibody (sdAb)), which binds to a target on the surface of HIV (such as HIV envelope glycoprotein gp120).

[0102] In some embodiments, the virus is a pneumonia virus. In some embodiments, the pneumonia virus is human respiratory syncytial virus (RSV). In some embodiments, the target combined with the second agent is RSV fusion (F) protein. In some embodiments, the second agent specifically binds to the target expressed on the RSV surface. In some embodiments, the second agent is an antibody or its antibody fragment (e.g., fragment antigen binding (Fab) fragment, single-chain variable fragment (ScFv) or single domain antibody (sdAb)), which is combined with the target (such as RSV F protein) on the surface of RSV.

[0103] In some embodiments, the pathogen is an antibacterial. In some embodiments, the antibacterial is Pasteurella, Staphylococcus, Streptococcus, Bacillus, Corynebacterium, Diphtheroids, Listeria, Erysipelothrix, Clostridium, Neisseria, Branhamella, Escherichia, Enterobacter, Proteus, Pseudomonas, Klebsiella, Salmonella, Shigella, Serratia, Acinetobacter, Haemophilus, Brucella, Yersinia, Francisella, Pasteurella, Vibrio, Flavobacterium, Pseudomonas, Campylobacter, Bacteroides, Fusobacterium, Scabies, Streptococcus or Legionella. In some embodiments, the second agent is specifically bound to the target expressed on the surface of antibacterial. In some embodiments, the second agent is an antibody or its antibody fragment (for example, fragment antigen binding (Fab) fragment, single-chain variable fragment (scFv) or single domain antibody (sdAb)), which is combined with the target on the surface of antibacterial.

[0104] In some embodiments, the pathogen is a parasite. In some embodiments, the parasite is Plasmodium, Trypanosoma, Toxoplasma, Leishmania or Cryptosporidium. In some embodiments, the Plasmodium is Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, Plasmodium knowlesi, Plasmodium ovale subspecies Cohen or Plasmodium ovale subspecies wollastonii. In some embodiments, the target combined with the second agent is a Plasmodium surface protein, such as merozoite surface protein 1 (MSP-1). In some embodiments, the second agent specifically binds to a target expressed on the surface of the parasite. In some embodiments, the second agent is an antibody or its antibody fragment (e.g., fragment antigen binding (Fab) fragment, single-chain variable fragment (ScFv) or nano antibody or single domain antibody (sdAb)), which is combined with a target on the surface of the parasite (e.g., a target on the surface of the plasmodium). In some embodiments, the target on the surface of the malarial parasite is a plasmodium surface protein, for example, merozoite surface protein 1 (MSP-1). In some embodiments, the second agent is an antibody that binds to MSP-1, optionally wherein the antibody is a nanobody. In some embodiments, the antibody comprises CDR-H1, CDR-H2, and CDR-H3 of any one of the antibodies listed in Table 1. In some embodiments, the antibody comprises an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, or at least 99%) identical to any one of SEQ ID NOs: 6-17. In some embodiments, the antibody comprises the amino acid sequence of any one of SEQ ID NOs: 6-17.

[0105] In some embodiments, the second agent specifically binds to a target present on the surface of a cancer cell. In some embodiments, the cancer cell is a blood cancer cell, a lung cancer cell, a breast cancer cell, a brain cancer cell, a gastrointestinal cancer cell, a liver cancer cell, a kidney cancer cell, a bladder cancer cell, a pancreatic cancer cell, an ovarian cancer cell, a testicular cancer cell, a prostate cancer cell, an endometrial cancer cell, a muscle cancer cell, a bone cancer cell, a neuroendocrine cancer cell, a connective tissue cancer cell, a head and neck cancer cell, or a skin cancer cell. In some embodiments, the cancer cell is a human cancer cell. In some embodiments, the target to which the second agent binds is a tumor-associated antigen, such as, but not limited to, MHC class I polypeptide-related sequence A (MICA) protein, MHC class I polypeptide-related sequence B (MICB) protein, folate receptor, fibronectin splice variant, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor 2 (VEGFR-2), CXC chemokine receptor type 4 (CXCR4), urokinase plasminogen activator surface receptor (uPAR), follicle-stimulating hormone receptor (FSHR), epithelial cell adhesion molecule (EpCAM), epithelial cadherin (ECAD), carcinoembryonic antigen (CEA) or mesothelin (MSLN). In some embodiments, the second agent is a small molecule (e.g., a small molecule inhibitor) that binds to a target on the surface of a cancer cell (e.g., a tumor-associated antigen). In some embodiments, the second agent is an antibody or an antibody fragment thereof (e.g., a fragment antigen binding (Fab) fragment, a single chain variable fragment (ScFv), or a single domain antibody (sdAb)) that binds to a target on the surface of a cancer cell (e.g., a tumor-associated antigen). In some embodiments, the second agent is an antibody that binds to MICA, optionally wherein the antibody is a nanobody. In some embodiments, the antibody comprises CDR-H1, CDR-H2, and CDR-H3 of any one of the antibodies listed in Table 2. In some embodiments, the antibody comprises an amino acid sequence that is at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, or at least 99%) identical to any one of SEQ ID NOs: 19-27. In some embodiments, the antibody comprises an amino acid sequence of any one of SEQ ID NOs: 19-27.

[0106] In some embodiments, the cell is a cancerous bone marrow cell or a healthy bone marrow cell. In some embodiments, the target to which the second agent binds is a bone marrow-associated antigen, such as, but not limited to, cluster of differentiation antigen 45 (CD45). In some embodiments, the second agent is an antibody or an antibody fragment thereof (e.g., a fragment antigen-binding (Fab) fragment, a single-chain variable fragment (ScFv), or a single-domain antibody (sdAb)) that binds to a target on the surface of a bone marrow cell, such as a bone marrow-associated antigen.

[0107] In some embodiments, the cell is a cancerous immune cell or a healthy immune cell, such as, but not limited to, a cancerous T cell or B cell, or a healthy T cell or B cell. In some embodiments, the target bound to the second agent is an immune cell-associated antigen, such as, but not limited to, cluster of differentiation antigen 4 (CD4), cluster of differentiation antigen 8 (CD8), T cell receptor (TCR) or B cell receptor (BCR). In some embodiments, the second agent is an antibody or an antibody fragment thereof (e.g., fragment antigen binding (Fab) fragment, single chain variable fragment (ScFv) or single domain antibody (sdAb)), which binds to a target on the surface of an immune cell (e.g., an immune cell-associated antigen).

[0108] In some embodiments, the conjugates provided herein provide therapeutic effects when applied to a subject. In some embodiments, the conjugates provided herein provide, when applied to a subject, the conjugates enhance the association (approach) between one or more immune cells (e.g., one or more immune cell types) expressing a crystallizable fragment (Fc) receptor and a cell or pathogen. In some embodiments, administering the conjugates provided herein to a subject causes the killing of cells or pathogens in the subject's body. In some embodiments, administering the conjugates provided herein to a subject causes the inactivation of cells or pathogens in the subject's body. In some embodiments, the subject to which the conjugates provided herein provide therapeutic effects is a mammal. In some embodiments, the subject to which the conjugates provided herein provide therapeutic effects is a human.

[0109] Composition

[0110] In some embodiments, the compositions of the present disclosure (e.g., pharmaceutical compositions) comprise a conjugate as described herein. In some embodiments, the compositions of the present disclosure (e.g., pharmaceutical compositions) comprise two or more conjugates as described herein. In some embodiments, the compositions comprising two or more conjugates comprise two or more conjugates that are specific for the same antigen. In some embodiments, the compositions comprising two or more conjugates comprise only one conjugate that is specific for each antigen. As contemplated herein, the terms "composition" and "preparation" may be used interchangeably.

[0111] In some embodiments, composition can include one or more conjugates described herein and one or more pharmacologically acceptable excipients.Pharmacologically acceptable excipients can enhance the stability of conjugates described herein, enhance the delivery of the conjugate to the cells (e.g., immune cells) of the object administering the composition, allow the conjugate to continue or delay release after administration, change the biodistribution of the conjugate (e.g., making the conjugate target specific tissues or cell types), or reduce the host's immunity to the conjugate. The example of a pharmacologically acceptable excipient includes any and all solvents, dispersion media, diluents or other liquid vehicles, dispersion or suspension aids, surfactants, isotonic agents, thickeners or emulsifiers and preservatives as known in the art. In some embodiments, a pharmacologically acceptable excipient includes an aqueous solution or buffer. In some embodiments, the composition is isotonic relative to the biological fluid (i.e., blood) of the object to which the composition is administered. In some embodiments, the pH of the composition is between 7 and 8, or the optimal pH is about 7.4.

[0112] Reagent test kit

[0113] The present disclosure also encompasses kits (e.g., pharmaceutical packs). The kits provided may comprise a pharmaceutical composition or conjugate described herein and a container (e.g., a vial, an ampoule, a bottle, a syringe, and / or a dispenser package or other container suitable for storage and / or administration). In some embodiments, the kit provided may optionally further comprise a second container comprising a pharmaceutical excipient for diluting or suspending the pharmaceutical composition or conjugate described herein. In some embodiments, the pharmaceutical composition or conjugate described herein is provided in a first container and combined with a second container to form a dosage unit.

[0114] Thus, in one aspect, provided herein are kits comprising a first container comprising a conjugate or pharmaceutical composition as described herein. In certain embodiments, the kits can be used to enhance or elicit an immune response of a specific cell or pathogen in a subject (e.g., a pathogenic cell or cells of a subject). In certain embodiments, the kits can be used to treat a disease in a subject in need thereof (e.g., a disease caused by a virus, a disease caused by a bacterium, a disease caused by a parasite, a disease caused by a fungus, a cancer). In certain embodiments, the kits can be used to prevent a disease in a subject in need thereof (e.g., a disease caused by a virus, a disease caused by a bacterium, a disease caused by a parasite, a disease caused by a fungus, a cancer).

[0115] In certain embodiments, the kit described herein further includes instructions for using the pharmaceutical composition or conjugate contained in the kit. Kit described herein may also include information as required by regulatory agencies (such as the U.S. Food and Drug Administration (USFood and Drug Administration, FDA)). In certain embodiments, the information contained in the kit is prescription information. In certain embodiments, the kit and instructions are used to enhance or elicit an immune response of cells or pathogens (e.g., pathogenic cells or cells of the object) in the object. In certain embodiments, the kit and instructions are used to treat a disease (e.g., a disease caused by a virus, a disease caused by bacteria, a disease caused by a parasite, a disease caused by a fungus, cancer) in a subject in need. In certain embodiments, the kit and instructions are used to prevent a disease (e.g., a disease caused by a virus, a disease caused by bacteria, a disease caused by a parasite, a disease caused by a fungus, cancer) in a subject in need. Kit described herein may include one or more additional medicaments as described herein as a separate composition.

[0116] Administration of the conjugate

[0117] The terms "treatment," "treat," and "treating" refer to reversing, alleviating, delaying the onset of, or inhibiting the progression of, a disease described herein (e.g., a disease caused by a virus, a disease caused by a bacterium, a disease caused by a parasite, a disease caused by a fungus, a cancer). In some embodiments, treatment may be administered after the subject has developed one or more signs or symptoms of the disease or has been observed in the subject. In other embodiments, treatment may be administered in the absence of signs or symptoms of the disease. For example, treatment may be administered to a susceptible subject before the onset of symptoms (e.g., in view of a history of symptoms of the disease, in view of the risk of recurrence or recurrence of the disease, and / or in view of exposure to a pathogen causing the disease or the possibility of future exposure to a pathogen causing the disease). After the symptoms subside, treatment may also be continued, for example to delay or prevent recurrence or recurrence. Prophylactic treatment refers to treatment of a subject who is not suffering from the disease but is at risk of suffering from the disease or a subject who has had the disease and is at risk of recurrence or regression of the disease. In some embodiments, the subject is at a higher risk of suffering from the disease or has a higher risk of recurrence or regression of the disease than an average healthy member of the population.

[0118] An "effective amount" of a composition described herein refers to an amount sufficient to elicit a desired biological response. The effective amount of a composition described herein can vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the conjugate described herein, the condition being treated, the mode of administration, and the age and health of the subject. In some embodiments, the effective amount is a therapeutically effective amount. In some embodiments, the effective amount is an amount sufficient for prophylactic treatment. In some embodiments, the effective amount is the amount of the conjugate described herein administered in a single dose. In some embodiments, the effective amount is the combined amount (sum) of the conjugates described herein administered in multiple doses. When the effective amount of a composition is mentioned herein, it is expressed as an amount that is therapeutically and / or prophylactically effective, depending on the subject and / or disease to be treated. Determining the effective amount and / or dosage is within the capabilities of those skilled in the art.

[0119] The terms "administer," "administering," or "administration" refer to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing a composition or conjugate described herein into or on a subject. The compositions or conjugates described herein can be administered systemically (e.g., by intravenous injection) or topically (e.g., by local injection). In some embodiments, the compositions or conjugates described herein are administered orally, intravenously, topically, intranasally, or sublingually. Parenteral administration is also contemplated. As used herein, the term "parenteral" encompasses subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, intradermal, and intracranial injection or infusion techniques. In some embodiments, administration is performed intramuscularly, intradermally, orally, intravenously, topically, intranasally, intravaginally, or sublingually. In some embodiments, the compositions or conjugates described herein are administered prophylactically.

[0120] In some embodiments, the compositions or conjugates described herein are administered once or repeatedly (e.g., 2, 3, 4, 5, or more times). For multiple administrations, administration can be performed over a period of time (e.g., 1 day, 1 week, 1 month, 6 months, 1 year, 2 years, 5 years, 10 years, or longer). For repeated administrations, administration can be performed over a fixed period of time (e.g., 1 day, 1 week, 1 month, 6 months, 1 year, 2 years, 5 years, 10 years, or longer) or over a variable period of time. In some embodiments, a composition or conjugate described herein is administered twice (e.g., day 0 and day 7, day 0 and day 14, day 0 and day 21, day 0 and day 28, day 0 and day 60, day 0 and day 90, day 0 and day 120, day 0 and day 150, day 0 and day 180, day 0 and 3 months later, day 0 and 6 months later, day 0 and 9 months later, day 0 and 12 months later, day 0 and 18 months later, day 0 and 2 years later, day 0 and 5 years later, or day 0 and 10 years later). In some embodiments, a composition or conjugate described herein is administered more than twice, until the subject has no symptoms of a disease (e.g., a disease caused by a virus, a disease caused by bacteria, a disease caused by a parasite, a disease caused by a fungus, cancer), or until the risk of developing the disease subsides.

[0121] In some embodiments, for the purpose of enhancing or eliciting an immune response of cells or pathogens (e.g., pathogenic cells or cells of a subject), a composition or conjugate as described herein is administered to a subject. In some embodiments, for the purpose of treating or preventing infection by a pathogen, a composition or conjugate as described herein is administered to a subject. In some embodiments, for the purpose of treating or preventing infection by a virus, a composition or conjugate as described herein is administered to a subject. In some embodiments, for the purpose of treating or preventing infection by a bacteria, a composition or conjugate as described herein is administered to a subject. In some embodiments, for the purpose of treating or preventing infection by a parasite, a composition or conjugate as described herein is administered to a subject. In some embodiments, for the purpose of treating or preventing infection by a fungus, a composition or conjugate as described herein is administered to a subject. In some embodiments, for the purpose of treating or preventing cancer, a composition or conjugate as described herein is administered to a subject.

[0122] In some embodiments, the compositions described herein or conjugates are administered to a subject to enhance or trigger an innate (cell-mediated) immune response in the subject. In some embodiments, after the compositions described herein or conjugates are administered to a subject, the conjugate is combined with cells or pathogens in the subject and the immunoglobulin of the subject, wherein the immunoglobulin is further combined with the immune cells of the subject, and the immune cells express crystallizable fragment (Fc) receptors on their surface. In some embodiments, the immunoglobulin of the subject comprises immunoglobulin kappa light chain or immunoglobulin lambda light chain. In some embodiments, the immunoglobulin of the subject comprises immunoglobulin kappa light chain. In some embodiments, the immune cells are macrophages, dendritic cells, natural killer cells, neutrophils, basophils, eosinophils or mast cells. In some embodiments, the immune cells are induced to produce one or more cytokines or chemokines by administering the compositions described herein or conjugates. In some embodiments, the immune cells are induced to produce one or more proinflammatory cytokines or proinflammatory chemokines by administering the compositions described herein or conjugates. In some embodiments, administration of a composition or conjugate described herein induces phagocytosis of cells or pathogens in the subject by the subject's immune cells. In some embodiments, administration of a composition or conjugate described herein causes killing of cells or pathogens in the subject. In some embodiments, administration of a composition or conjugate described herein causes inactivation of cells or pathogens in the subject (i.e., the cells or pathogens are no longer able to replicate or reproduce).

[0123] In some embodiments, the subject is a subject with a pathogen infection (e.g., a viral infection, a bacterial infection, a parasitic infection, a fungal infection) or a risk of infection with the pathogen. In some embodiments, the subject is suffering from or is at risk of developing a cancer such as, but not limited to, a blood cancer, a lung cancer, a breast cancer, a brain cancer, a gastrointestinal cancer, a liver cancer, a kidney cancer, a bladder cancer, a pancreatic cancer, an ovarian cancer, a testicular cancer, a prostate cancer, an endometrial cancer, a muscle cancer, a bone cancer, a neuroendocrine cancer, a connective tissue cancer, a head and neck cancer, or a skin cancer. In some embodiments, the cancer is a metastatic cancer.

[0124] As defined herein, a "subject" refers to a living organism to which administration is contemplated. In some embodiments, the subject is a mammal. In some embodiments, the subject is a non-human animal (e.g., a primate (e.g., cynomolgus macaque or rhesus macaque), a commercially relevant mammal (e.g., cattle, pigs, horses, sheep, goats, cats, or dogs), or a bird (e.g., a commercially relevant bird such as a chicken, duck, goose, or turkey)). In some embodiments, the subject is a domesticated animal (e.g., cattle, pigs, horses, sheep, goats) or a companion animal (i.e., a pet or service animal, such as a cat or dog). In some embodiments, the subject is a fish, a reptile, or an amphibian. The non-human animal can be a male or female animal at any stage of development. The non-human animal can be a transgenic animal or a genetically engineered animal.

[0125] In some embodiments, the subject is a human. In some embodiments, the subject is a human infant. In some embodiments, the human infant is a neonate less than 28 days old. In some embodiments, the human infant is less than 1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 days old at the time of administration.

[0126] In some embodiments, the human subject is over 28 days old (e.g., 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 2 years, 3 years, 4 years, 5 years, 10 years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years, 17 years). In some embodiments, the human subject is an adult (e.g., over 18 years old). In some embodiments, the human subject is an elderly subject (e.g., over 60 years old). In some embodiments, the human subject is 60, 65, 70, 75, 80, 85, 90, 95, 100 years old or older.

[0127] In some embodiments, the human subject is part of one or more immune-vulnerable populations. In some embodiments, the human subject is frail (e.g., a subject with frailty syndrome, a malnourished subject, or a subject with a chronic disease that causes frailty). In some embodiments, the human subject has a weak immune system, such as an underdeveloped immune system (e.g., an infant or newborn subject), an aging immune system (e.g., an elderly subject), or an impaired immune system. Subjects with an aging immune system include, but are not limited to, subjects who exhibit a decline in immune function associated with advanced age. Subjects with an impaired immune system include, but are not limited to, subjects with primary or acquired immunodeficiency, such as subjects with sepsis, HIV infection, and cancer, including subjects who are receiving chemotherapy and / or radiotherapy, and subjects who are administering immunosuppressants (e.g., for organ or tissue transplantation). In some embodiments, the human subject suffers from or is suspected of having one or more conditions or diseases that reduce the immune system function of the subject and / or increase the risk of infection by one or more pathogens (e.g., viruses, bacteria, parasites, fungi). In some embodiments, the human subject is, for example, a subject suffering from or suspected of having chronic lung disease, asthma, cardiovascular disease, cancer, metabolic disorders (e.g., obesity or diabetes), chronic kidney disease, or liver disease.

[0128] The following examples will help to more fully understand some embodiments, advantages, features and uses of the technology disclosed herein. These examples are intended to illustrate some benefits of the present disclosure and describe specific embodiments, but are not intended to illustrate the full scope of the present disclosure and therefore do not limit the scope of the present disclosure.

[0129] Example

[0130] Example 1 - Nanobody-drug adducts for the treatment of influenza

[0131] Influenza is a potentially life-threatening acute respiratory infection caused by influenza viruses. Influenza A and influenza B viruses, which are usually spread during seasonal influenza epidemics, may cause human influenza. The cost of influenza epidemics is very high every year. It is estimated that influenza epidemics cause 3 million to 5 million severe influenza cases per year, and 250,000 to 500,000 deaths per year, including approximately 12,000 to 79,000 deaths per year in the U.S. Influenza viruses also pose a major health risk to human society because they are highly contagious, and new influenza variants may be transmitted to humans from animal hosts (for example, non-human mammals or bird species) comprising many migratory bird species. Due to these factors, influenza viruses are particularly prone to causing pandemics. In fact, at least four independent influenza pandemics occurred in the last century (for example, 1918 to 1920, 1957 to 1958, 1968 to 1969 and 2009 to 2010), and have caused the deaths of tens of millions of people in total.

[0132] Fortunately, several therapeutic agents have been clinically approved for the treatment of influenza infection. These therapeutic agents include several antiviral agents of molecular features on the surface of specific target influenza virus particles and infected cells, and include, for example, zanamivir, oseltamivir and peramivir, which specifically bind to and inhibit the neuraminidase encoded by influenza A virus and influenza B virus, thereby preventing the infected cells from releasing new virions. Although the timely administration of these therapeutic agents can reduce the duration of influenza infection by about 1 to 2 days, it is not clear whether the administration truly reduces the risk of individual development of severe disease (for example, disease requiring hospitalization). In addition, it is not clear whether these therapeutic agents can effectively prevent infection when administered prophylactically, and therefore, due to the risk of adverse drug reactions, it is not recommended to use these therapeutic agents prophylactically.

[0133] One approach to improving the efficacy of influenza treatment is to fuse an influenza-specific therapeutic agent with another agent that can bind to polyclonal immunoglobulins produced by the host. The bound immunoglobulins can then recruit immune cells that express Fc receptors on their surfaces and then kill or inactivate the recruited viral particles or infected cells. This strategy can be achieved, for example, by combining an existing influenza-specific therapeutic agent (such as zanamivir) with an antibody or antibody fragment that broadly binds to host immunoglobulins (such as the variable region of the heavy chain of a camelid antibody (VHH) that is specific for kappa light chains). κ)) fusion (Figure 1). This strategy can potentially be used to stimulate a stronger immune response to influenza than other achievable immune responses, because any host immunoglobulin containing a kappa light chain and an Fc region can be used to recruit immune cells against influenza virus particles or infected cells, regardless of the specificity of the host immunoglobulin. Although with VHH κ The fused zanamivir may retain its inhibitory activity, but in principle any agent that is specific for one or more targets on the surface of influenza virus particles and / or influenza-infected cells may be used, including, for example, antibodies or antibody fragments specific for viral neuraminidase or hemagglutinin. In addition, compared to the free drug alone, the inhibitory activity of the VHH κ The fusion of can also enhance the blood circulation half-life of zanamivir or other influenza-specific therapeutic agents, thereby further enhancing the efficacy of the therapeutic agent.

[0134] In vitro testing of VHHs κ To evaluate the efficacy of this strategy, we used different concentrations of VHH fused to biotin. κ (VHH κ -biotin) were exposed to mouse IgG2b coated enzyme-linked immunosorbent assay (ELISA) plates. For this assay, commercially available anti-mouse kappa chain VHHs (Nanobody clone TP1170) were used. Horseradish peroxidase fused to streptavidin (HRP-streptavidin) was then used as a secondary agent to detect the VHHs. κ - Binding between biotin and IgG2b of the plate. As a control, a single Nanobody SD36 specific for influenza hemagglutinin but not kappa light chain was fused to biotin (SD36-biotin) and SD36-biotin was fused to VHH κ Fusion (VHH κ -SD36-biotin-1 and VHH κ -SD36-biotin-2) and tested. After incubation for 2 hours at ambient temperature, the ELISA plate was washed and then incubated with streptavidin-HRP, followed by washing, treatment with TMB substrate solution (Biolegend, catalog number: 421101), quenching with H2SO4, and measurement. The dissociation constant (K) was calculated based on the plot of the average absorbance value at 450 nm versus the concentration of VHH. d ). VHH κ -Biotin, VHH κ -SD36-biotin-1 and VHH κ -SD36-biotin-2 each binds to mouse IgG2b with low nanomolar affinity (dissociation constant K d 2.0nM to 2.4nM)( Figure 2 ). In contrast, no binding between SD36-biotin and IgG2b was detected. These results confirm that VHH κ High specificity for host immunoglobulins and indicates that VHH κ Fusion with agents specific for influenza can effectively recruit host immunoglobulins and immune cells to influenza virions and infected cells.

[0135] Then a VHH was designed κ Methods for covalently linking to influenza-specific agents such as zanamivir. Although any cleavable or non-cleavable linker can be used in principle, a method was developed to modify zanamivir by attaching a triglycine dibenzylcyclooctyne (DBCO) linker to the 7-hydroxyl group of zanamivir. First, a ligand targeting zanamivir was prepared ( Figure 3A ), which is then reacted with Gly-Gly-Gly-DBCO to produce Gly-Gly-Gly-zanamivir ( Figure 3B Then, Gly-Gly-Gly-zanamivir was reacted with VHH using a sortase (sortase A; SrtA) reaction. κ The C-terminal amino acid residues of LPETGGH6 were fused to generate VHH κ -Zanamivir adduct ( Figure 3C ). Briefly, five mutant sortase A was used to catalyze the reaction of sortase-compatible nucleophiles with VHHs. κ The addition of a C-terminal LPETG motif was performed. The sortase reaction was performed in PBS containing 20 μM sortase A and 10 μM CaCl2. After incubation at 4°C overnight, Ni-NTA beads were added to the reaction mixture and incubated for 30 minutes. Unreacted VHH and His-tagged sortase A were removed at 4°C. The reaction mixture was then loaded onto a PD-10 desalting column to remove excess nucleophile. VHH synthesized by this method κ The zanamivir adduct was subsequently determined by SDS-PAGE and mass spectrometry to be approximately 14 kDa in size and essentially pure ( Figure 4A and 4B ).

[0136] VHHs were then evaluated in vitro using influenza-infected cell cultures. κ -Specificity of zanamivir adducts for influenza-infected cells. Madin-Darby canine kidney (MDCK) cells were infected with influenza virus and expressed neuraminidase 24 hours after infection. At this time, different concentrations of VHH were used. κ -zanamivir adducts were used to treat infected MDCK cells. κThe binding between the -zanamivir adduct and the infected cells was measured by saturation binding assay. Briefly, the culture medium in the infected cells was removed and replaced with culture medium containing different concentrations of the adduct. After incubation for 1 hour, the infected cells were washed and treated with mouse IgG-phycoerythrin (R&D Systems #IC002P) in fresh serum-free medium. After incubation for 30 minutes, the infected cells were washed and dissolved in 1% sodium dodecyl sulfate (SDS) in water, and the cell-associated fluorescence was measured using an excitation wavelength of 560 nm and an emission wavelength of 620 nm. The dissociation constant (K) was calculated from a plot of cell-bound fluorescence intensity versus the concentration of the VHH. d ). Similar to the previously observed VHH κ Specificity for IgG ( Figure 2 ), VHH κ -Zanamivir adducts exhibit low nanomolar specificity for influenza A virus ( Figure 5A and 5B ). In addition, VHH κ - Zanamivir adducts were tested against two other influenza A strains A / Wisconsin / 629-D00015 / 2009 (H1N1 subtype) ( Figure 5A ) and A / Hong Kong / 8 / 1968 (H3N2 influenza subtype) ( Figure 5B ) showed low nanomolar specificity in MDCK cells infected with VHH. κ - Zanamivir adducts were tested against two other influenza B strains, B / Florida / 4 / 2006 ( Figure 5C ) and B / Brisbane / 60 / 2008( Figure 5D ) infected MDCK cells showed low nanomolar specificity. These results confirm that VHH κ -Zanamivir adducts are as specific for influenza neuraminidase as free zanamivir and should be effective in treating a range of influenza subtypes.

[0137] Determination of VHHs in vitro κ - After the efficacy of zanamivir adducts, VHH κ -zanamivir adducts were evaluated. Mice were infected with 50 μL of influenza A virus A / Puerto Rico / 8 / 1934 (an H1N1 subtype) on day 0. The LD of 50 μL of influenza A virus A / Puerto Rico / 8 / 1934 was 50 Equivalent to the LD of influenza A virus A / Puerto Rico / 8 / 1934 50 Then different amounts of VHH were intraperitoneally administered to mice. κ- Zanamivir adduct (0.1 mg / kg, 1 mg / kg or 3 mg / kg), 1 mg / kg of non-covalently fused VHH κ and zanamivir or mock-treated with phosphate-buffered saline (PBS). κ -zanamivir adduct-treated mice received VHH only on day 0 or on days 0, 2, and 4 post-infection κ -zanamivir adducts. κ -zanamivir adducts, the body weight (mass) and survival rate of infected mice were monitored once a day for 14 days ( Figure 6A and 6B ). PBS mock treatment and 0.1 mg / kg VHH κ Mice treated with Zanamivir-adducts showed significant weight loss and complete lethality on days 8 and 10 after infection, respectively. κ Mice treated with 1 mg / kg or 3 mg / kg of VHH κ -zanamivir adduct-treated mice did not suffer from weight loss or mortality due to influenza infection. In fact, mice treated with 3 mg / kg of VHH on days 0, 2, and 4 post-infection κ - Zanamivir adduct or 1 mg / kg VHH κ -Zanamivir adduct-treated mice gained modest weight within 14 days after infection.

[0138] To establish this efficacy against multiple virus species, mice were similarly infected with influenza A-A / California / 07 / 2009 (H1N1); influenza A-A / Hong Kong / 1 / 1968; or influenza B-B / Florida / 4 / 2006; and vaccinated on the same day with a single dose of VHH κ - Zanamivir (3 mg / kg) Figure 6C ). VHH κ - Zanamivir was shown to result in high survival of all infected mice up to 14 days.

[0139] Additional experiments were performed to delay the addition of VHH κ - Zanamivir (10 mg / kg) until day 1, 2, or 3 post-infection with influenza A-A / Puerto Rico / 8 / 1934 ( Figure 6D ). Treated mice showed high survival rates up to 14 days.

[0140] Finally, a prophylactic experiment was performed. Seven days before infection with influenza A-A / Puerto Rico / 8 / 1934, mice were administered VHHs.κ - Zanamivir (5 mg / kg) Figure 6E These data suggest that administration of VHHs prior to infection κ -Zanamivir resulted in a high survival rate.

[0141] These results indicate that administration of VHH κ Fusions with influenza-specific agents are highly effective in boosting immunity to influenza and reducing the risk of severe illness.

[0142] Although these results were obtained using mouse-specific VHHs in a mouse model, the results could be improved by simply transfecting the mouse-specific VHHs into κ with VHH specific for human kappa light chain κ Exchange can obtain VHHs that are effective in treating human influenza κ - Zanamivir adducts. As previously described, similar results can be obtained with any adduct containing an agent that is specific for influenza virions and / or influenza infected cells, such as a small molecule or peptide specific for hemagglutinin, or an antibody or antibody fragment (e.g., a nanobody) specific for neuraminidase, hemagglutinin, or another target (e.g., a protein) on the surface of influenza virions and / or infected cells. Unless designed to be specific for influenza A or influenza B, a VHH containing κ The adducts of are likely to be effective in treating both types of influenza, especially since zanamivir and other influenza therapeutics are known to be active against both influenza A and influenza B.

[0143] Example 2 - Nanobody-Nanobody adducts for the treatment of influenza

[0144] Alternatively, adducts containing immune cell specific nanobodies (e.g., VHHs) can be developed for the treatment of influenza. κ ) and influenza virus-specific nanobodies, rather than influenza-specific small molecules (such as zanamivir). To this end, the nanobody VHH κ Conjugated to a previously reported single domain antibody (VHH) specific for influenza virus hemagglutinin SD36 (see, e.g., Laursen et al., “Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin” 2018. Science, 362(6414), 598–602). VHH κ-SD36 adducts were prepared by first preparing a version of SD36 containing a terminal azide ( Figure 7A ) and VHH linked by Gly-Gly-Gly-Cys-DBCO (SEQ ID NO: 28) κ ( Figure 7B ), each prepared by a sortase reaction as described in Example 1. Each VHH was then combined to produce VHH κ -SD36 adduct ( Figure 7C The final product was purified by size exclusion chromatography using a Superdex 75 10 / 300 column. κ -SD36 adduct gene fusion version, in which VHH κ Connected to SD36 at the N-terminus via a flexible linker (GGGGS) 3 (SEQ ID NO: 29) Figure 7D ). Further generate VHH κ , SD36 and gene-conjugated VHH κ -Biotinylated version of SD36 ( Figures 8A-8C ). The amino acid sequence of the gene fusion conjugate is as follows:

[0145] VHH κ -SD36 nanobody conjugate:

[0146] QVQLVESGGGWVQPGGSLRLSCAASGFTFSDTAMMWVRQAPGKGREWVAAIDTGGGYTYYADSVKGRFTISRDNAKNTLYLQMNSLKPEDTARYYCAKTYSGNYYSNYTVANYGTTGRGTLVTVSSAAAGGGGSGGGGSGGG GSEVQLVESGGGLVQAGGSLKLSCAASGRTYAMGWFRQAPGKEREFVAHINALGTRTYYSDSVKGRFTISRDNAKNTEYLEMNNLKPEDTAVYYCTAQGQWRAAPVAVAAEYEFWGQGTQVTVSSGGLPETGGHHHHHH(SEQ ID NO:5).

[0147] Next, the same saturation binding assay as previously described ( Figure 5A and 5B ) to evaluate biotinylated SD36, VHH κ -SD36 and gene-conjugated VHH κ-SD36, except that cells incubated with SD36-biotin were treated with 10 μg / mL streptavidin-PE (Bio-Jin Biotech #405204). As expected, each VHH and VHH conjugate bound to influenza A hemagglutinin with low nanomolar affinity ( Figures 9A-9C ). Although VHH κ -SD36 and gene-conjugated VHH κ -SD36 both bind to influenza A virus-infected MDCK cells, but VHH synthesized by click chemistry κ -SD36 binds with higher affinity ( Figure 9C ).

[0148] Determination of VHHs in vitro κ -SD36 conjugates, as previously described ( Figure 6A and 6B ), each conjugate was evaluated in animal models. κ -SD36( Figure 6A ) or VHH conjugated by click chemistry κ -SD36( Figure 6B ) were completely protected against a lethal dose of influenza A virus, although mice treated with 10 mg / kg of either conjugate further showed no weight loss in response to influenza infection ( Figure 10A and 10B ).

[0149] Additional experiments were performed to delay the addition of VHH κ -SD36 (10 mg / kg) until day 1, 2, or 3 after infection with influenza A-A / Hong Kong / 1 / 1968 ( Figure 10C ). Treated mice showed high survival rates up to 14 days.

[0150] These results indicate that VHHs similar to those in Example 1 κ Zanamivir adducts, administered VHH κ Fusion with nanobodies targeting influenza antigens was highly effective in enhancing immunity to influenza and reducing the risk of severe disease.

[0151] Finally, VHH κ The in vivo half-life of the SD36 conjugate was evaluated. 89 Zr 4+ Stock solution and 2.0 M Na2CO3 treated VHH κ -SD36-DFO or SD36-DFO control for 1 hour to synthesize VHH κ-SD36 Zirconium-89( 89 Zr) radiolabeled version (generated by click chemistry) ( Figure 11A and 11B The location and half-life of the radiolabeled conjugate in mice were then assessed by immunopositron emission tomography (immunoPET). Briefly, mice were infected with a lethal dose (10 LD 50 Mice infected with influenza virus A / Hong Kong / 8 / 1968 (H3N2) were injected with attenuated radiolabeled SD36-DFO or VHH κ -SD36-DFO and scan every 24 hours to determine SD36-DFO or VHH κ - Location and overall level of SD36-DFO ( Figure 12 ). It was observed that compared to SD36 alone, anti-mouse VHH κ -SD36-DFO has a prolonged half-life in vivo and accumulates to a greater extent at sites of infection, especially in the lungs.

[0152] Together, these results suggest that VHH κ Flexibility of conjugates, as conjugates containing different modes of binding to influenza antigens (e.g., small molecules binding to neuraminidase versus nanobodies binding to hemagglutinin) have been shown to be effective in treating influenza and preventing severe disease.

[0153] Example 3 - Development of malaria-specific Nanobodies

[0154] Next, a VHH-containing construct specific for another pathogen, Plasmodium falciparum, was developed. κ adducts. Plasmodium falciparum is a single-celled protozoan species and one of five parasites known to cause malaria in humans when transmitted by infected female Anopheles mosquitoes. The World Health Organization estimates that there were approximately 241 million cases of malaria worldwide in 2020, resulting in approximately 627,000 deaths. Cases caused by Plasmodium falciparum carry the highest risk of mortality. Although malaria is treatable and curable, particularly through the use of artemisinin-based combination therapies (ACTs), drug-resistant malaria is a growing threat to global health. In addition, although ACTs are generally effective, they are toxic and can cause fatigue, headache, dizziness, nausea, vomiting, and abdominal pain.

[0155] Example 1 demonstrates the use of the small molecule zanamivir in influenza virions and influenza-infected cells, while here a panel of VHH nanobodies specific for different regions of the Plasmodium falciparum merozoite surface protein 1 (MSP-1) was developed. MSP-1 is a propeptide (called p190) that consists of four subunits, p83, p30, p38, and p42, expressed at the onset of the asexual reproduction phase of Plasmodium parasites ( Figure 13A Once cleaved, these subunits can assemble on the surface of Plasmodium cells to form the mature MSP-1 complex for binding to erythrocytes on the surface and infecting them. The sequences of isolated VHHs that bind to MSP-1 are shown in Table 1 below.

[0156] Table 1: Amino acid sequences of VHHs specific for Plasmodium falciparum MSP-1

[0157]

[0158] The purified VHH nanobodies were biotinylated and tested for their specificity against isolated MSP-1 subunits. Anti-p83 B4, anti-p38 B8, anti-p42 A6, and anti-p42 G11 VHHs were each incubated with plate-bound p83, p38, p42, and p42, and binding to the plate was detected by enzyme-linked immunosorbent assay (ELISA) using streptavidin-horseradish peroxidase (HRP) and tetramethylbenzidine (TMB). Each VHH was observed to bind specifically to one subunit of the MSP-1 complex, while the control VHH did not bind ( Figure 13B This binding was further confirmed by subsequent gel electrophoresis, which showed that each antibody bound to one subunit of MSP-1 and the MSP-1 propeptide (p190), but not to any other subunit ( Figure 13C ). VHH clones B4 and B8 were also tested on lysates from 3D7 merozoites that were approximately 38 to 44 hours old, and binding was observed. Finally, the purified VHHs were tested in a flow cytometry assay on 3D7 merozoites that were approximately 38 to 44 hours old. Cy5 fluorescently labeled VHHs were observed to bind specifically to live Plasmodium merozoites, with the fluorescence intensity of the binding being greater than that observed for control VHHs, anti-major histocompatibility complex II (MHC-II) ( Figure 13D ).

[0159] Together, these data demonstrate the specificity of VHH nanobodies targeting Plasmodium parasites and provide proof-of-concept that VHH-containing κ Adducts with any of these VHHs may be effectively used to treat malaria in a similar manner as demonstrated for the treatment of influenza (as demonstrated in Example 1).

[0160] Example 4 - Nanobody-drug adducts for enhancing immunity against cancer cells

[0161] The efficacy of adducts targeting pathogens (Examples 1 and 2), as well as the development of Nanobodies for use in Nanobody-Nanobody adducts for the treatment of diseases caused by pathogens (Examples 2 and 3) have been shown above. κ The adducts can be further used to enhance or elicit immune responses against cancer. κ and a previously reported adduct of a VHH targeting murine major histocompatibility complex II (MHC-II) (see Fang et al., “Structurally Defined αMHC-II Nanobody-Drug Conjugates: A Therapeutic and Imaging System for B-Cell Lymphoma” 2016. Angewandte Chemie, 55(7), 2416–2420). Although MHC-II is typically located on the surface of professional antigen-presenting cells (e.g., dendritic cells), it is also expressed on the surface of lymphocytes (including certain lymphomas). Therefore, adducts containing nanobodies targeting MHC-II can be used to recruit immune cells to lymphoma cells. Similar to the previously prepared adduct targeting influenza hemagglutinin ( Figures 7A-7C ), synthesizing VHH using click chemistry κ -VHH7 adduct ( Figures 14A-14C ). The amino acid sequence of VHH7 before conjugation is as follows:

[0162] VHH7 Nanobody:

[0163] QVQLQESGGGLVQAGDSLRLSCAASGRTFSRGVMGWFRRAPGKEREFVAIFSGSSWSGRSTYYSDSVKGRFTISRDDNAKNTVYLQMNGLKPEDTAVYYCAAGYPEAYSAYGRESTYDYWGQGTQVTVSSGG (SEQ ID NO: 18).

[0164] VHH κ The -VHH7 adducts were then tested in vitro against the mouse lymphoma cell line A20 cells in a complement dependent cytotoxicity (CDC) assay. Briefly, A20 cells were plated in 96-well white-walled plates and stained with anti-mouse VHH κ-VHH7 adducts or anti-mouse VHH κ After incubation at ambient temperature for 30 minutes, fresh serum-free medium containing normal mouse IgG isotype control (Invitrogen #10400C) and 40% (v / v) rabbit complement serum (Sigma-Aldrich #S7764) were added to the cells. After further incubation at 37°C for 4 hours, the cells were incubated with a mixture of VHH7 and VHH7 (final concentrations: 10 nM and 100 nM). Cell viability was measured using a luminescent cell viability assay (Promega #G7572). Maximum killing was measured by treating cells with 5% H2O2. κ The percentage of cytotoxicity induced by the -VHH7 adducts was calculated as follows:

[0165] Cytotoxicity % = (luminescence 不含VHH - Glow 含VHH ) / (luminous 不含VHH - Glow 最大杀伤 ) × 100. Discover VHH κ The -VHH7 adducts were effective in inducing cytotoxicity in A20 cells at both 10 nM and 100 nM, whereas treatment with each component alone failed to induce cytotoxicity ( Figure 15A and 15B ).

[0166] The antibody-dependent cellular cytotoxicity (ADCC) assay further demonstrated that the VHH κ -Efficacy of VHH7 adducts. In short, by EasySep TM Mouse NK cell isolation kit (STEMCELL, #19855RF) was used to collect murine natural killer (NK) cells from the spleen of BALB / c mice for use as in vitro effector cells. A20 cells were plated in 96-well plates and stained with anti-mouse VHH κ -VHH7 adducts or anti-mouse VHH κ The cells were treated with a mixture of VHH7 and VHH7 (final concentrations: 10 nM and 100 nM), and then treated with mouse IgG2aκ isotype control antibody (final concentration: 20 μg / mL). After incubation for 30 minutes, 1×10 6 Murine NK cell suspension was added to 10 cells / well and further incubated at 37°C for 4 hours. Cell viability was measured using a non-radioactive cytotoxicity assay (LDH) (Promega, #G1780) where absorbance at 490 nm was measured. Spontaneous signaling generated by effector cells alone was also assessed. κThe percentage of total lysis induced by the VHH7 adduct was calculated as follows: Total lysis % = (A490 实验性 –A490 效应子自发性 ) / (A490 靶标最大值 ) × 100. As expected, VHH κ -VHH7 adduct treatment resulted in approximately 30% to 40% of A20 cells being lysed within this timeframe at both 10 nM and 100 nM ( Figure 16A and 16B ). In addition, VHH κ -VHH7 adducts have greater efficacy than VHH alone κ These data demonstrate that, in addition to their use in treating pathogenic infections, VHH κ The adducts can also be used to effectively target and treat cancer cells by enhancing immune cell responses.

[0167] In use 10LD 50 VHHs were further tested in 6- to 9-week-old female BALB / c mice infected with influenza virus. κ -SD36 adducts. VHHs were added at the indicated doses. κ -SD36, VHH κ Mice were treated with a mixture of SD36 and SD36 or an equal volume of PBS by intraperitoneal injection. When the mice lost 25% of their body weight or became moribund, they were euthanized. The weight loss curve (left) and the survival rate curve ( Figure 14D These data demonstrate that VHH κ The -SD36 conjugate was effective in treating infected mice, as indicated by their high survival rate.

[0168] Example 5 - Nanobody-drug adducts for enhancing immunity against target pathogens or other cell types

[0169] The efficacy of the adducts for treating influenza and malaria infections has been demonstrated in Examples 1-3. In addition, the efficacy of the adducts for treating cancer has been demonstrated in Example 4. However, VHH κ Adducts can be modified in several ways to be specific for different pathogens and / or cell types. For example, VHH κ Alternatively, it may be linked to an agent that is specific for another target, such as a target (e.g., a protein) located on the surface of another pathogen, such as another virus, bacterium, parasite, or fungus. For example, a VHH κInstead of zanamivir, a small molecule, peptide, protein, carbohydrate, lipid, nucleotide, nucleic acid, oligonucleotide, aptamer or antibody (or antibody fragment) that specifically recognizes a target on the surface of a beta coronavirus (such as Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome (SARS)-related coronavirus (SARS-CoV)-1 or SARS-CoV-2) can be linked. For example, VHH κ Can be linked to an agent that specifically recognizes the MERS-CoV, SARS-CoV-1 or SARS-CoV-2 spike protein or its spike protein receptor binding domain (RBD) to produce a VHH that is specific for MERS-CoV, SARS-CoV-1 or SARS-CoV-2 infection and can be used for its treatment κ adducts. Similarly, VHH κ It can be linked to an agent specific for, for example, the human immunodeficiency virus (HIV) envelope glycoprotein gp120 to generate a VHH specific for HIV infection and useful for its treatment. κ Adducts. For example, VHH κ Can be linked to an agent specific for the human respiratory syncytial virus (RSV) fusion protein (F) to generate VHHs specific for RSV infection and useful for its treatment κ Adducts. VHHs that can be used to treat parasites (such as Plasmodium spp.) κ The adducts can be prepared, for example, by combining VHH κ The adducts can be linked to an agent specific for another merozoite surface protein 1 (MSP-1) or for another surface protein of the parasite. Similar strategies can also be used to generate adducts capable of recruiting host immunoglobulins and immune cells against infectious bacteria and fungi.

[0170] Alternatively, related strategies can be used to target host immunoglobulins and immune cells to the subject's own cells. For example, VHH κ Linking to agents specific for tumor-associated antigens to generate VHHs specific for cancer and useful for its treatment κAdducts, wherein the tumor-associated antigens are, but are not limited to, folate receptor, fibronectin splice variant, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor 2 (VEGFR-2), CXC chemokine receptor type 4 (CXCR4), urokinase plasminogen activator surface receptor (uPAR), follicle stimulating hormone receptor (FSHR), epithelial cell adhesion molecule (EpCAM), epithelial cadherin (ECAD), carcinoembryonic antigen (CEA) or mesothelin (MSLN). When systemically administered, such adducts can be used to target cancer cells throughout the body and are therefore particularly useful for treating metastatic cancer. Adducts can also be designed by combining VHH κ Linking to an agent specific for a target that is disproportionately expressed on the surface of target cells compared to non-target cells allows for targeting of host immunoglobulins and immune cells to other cell types, including cells that are undergoing or have undergone phenotypic changes in response to cellular stress. Additionally, adducts can be designed to target host immunoglobulins and immune cells to healthy as well as diseased cells. For example, by combining VHH κ Adducts specific for bone marrow can be produced by linking to agents specific for myeloid cells or their immediate precursors. Such agents can be used to ablate the bone marrow in a subject without the need for potentially harmful radiotherapy or chemotherapy agents typically administered prior to bone marrow transplantation. Similarly, by linking VHH κ By linking to an agent specific for a target cell (e.g., cluster of differentiation antigen 4 (CD4), cluster of differentiation antigen 8 (CD8), T cell receptor (TCR), or B cell receptor (BCR), adducts specific for healthy and / or diseased immune cells can be produced. Such adducts can be used, for example, to ablate immune cells specific for self-antigens (i.e., antigens associated with autoimmunity) or immune cells specific for a particular allergen.

[0171] Alternatively or in addition to any of the foregoing examples, the adducts may also be modified to include alternative antibodies or antibody fragments known in the art, such as whole antibodies, Fab fragments, or single chain variable fragments (ScFv). It is also possible to combine an agent specific for a target pathogen and / or cell with an agent specific for a lambda light chain (VHH) λ ) instead of VHH κ Heavy chains of camelid antibodies with specificity are linked to produce adducts that are specific and useful for enhancing immune responses against such target pathogens and / or cells. λ Adducts with VHH κ The adducts differ only in that they are specific for host immunoglobulins containing lambda light chains rather than kappa light chains. λThe adducts are able to bind to any host immunoglobulin comprising a lambda light chain and an Fc region to recruit immune cells to target pathogens and / or cells, regardless of the specificity of the host immunoglobulin.

[0172] As mentioned above, in principle any linker known in the art can be used to link VHH κ or VHH λ The linker can be a cleavable linker, such as a peptide linker, a disulfide linker, or a hydrazone linker, or a linker for covalently linking the target-specific agent to the VHH. κ or VHH λ The formation of the conjugate can be achieved by chemical reactions between the individual components of the conjugate or by the production of RNA- or DNA-based nucleic acid constructs that, when expressed in bacteria or eukaryotic cells, specify the amino acid sequence of the desired conjugate and produce the desired conjugate (e.g., with VHH κ or VHH λ Conjugated target-specific antibodies or antibody fragments (eg, target-specific nanobodies or single domain antibodies)).

[0173] Example 6 - Development of MICA-specific Nanobodies

[0174] MHC class I polypeptide-related sequence A (MICA), as a class I MHC-like molecule, is a glycoprotein induced by cell stress and is often found to be enriched on the surface of malignant transformed cells. MICA is recognized by natural killer group 2D (NKG2D), also known as killer cell lectin-like receptor K1 (KLRK1), an activating receptor on the surface of natural killer (NK) cells that can immunize MICA-positive targets (such as tumor cells). High levels of MICA expression are positively correlated with improved prognosis, for example in cholangiocarcinoma (see, for example, Oliviero B et al., Oncoimmunology 2022; 11(1): 2035919). Downregulation of MICA can occur through shedding, catalyzed by ADAM family matrix metalloproteinases (see, for example, Waldhauer I et al., Cancer Res 2008; 68(15): 6368-76). Loss of MICA surface expression renders tumor cells less sensitive to NKG2D-positive NK cells, while soluble MICA itself may occupy NKG2D receptors on NK cells and impair the interaction between NK cells and MICA-positive targets. VHH nanobodies specific for MICA could be used to selectively direct immune responses against MICA-positive tumor cells or, as part of VHH nanobody adducts, deliver cytotoxic or cytostatic agents to such cells for therapeutic purposes.

[0175] This article describes the generation of VHH nanobodies that specifically recognize MICA. Compared to conventional two-chain immunoglobulins, these nanobodies are expected to have a short circulation half-life and excellent tissue penetration, and have the desired properties of both in vivo imaging agents and immunotherapeutic agents. Because MICA is expressed on the surface of stressed cells and cancer cells, the ability to non-invasively detect such aberrations in vivo will be an important diagnostic tool for detecting premalignant and malignant lesions. MICA-specific nanobodies can also be used as part of therapeutic nanobody adducts.

[0176] In order to obtain MICA-specific VHH nanobodies, alpacas were immunized with the extracellular domain of purified MICA, and a phage display library was established from which MICA-specific nanobody sequences were isolated. Briefly, alpacas were immunized with 250 μg of purified MICA*009 in alum adjuvant, followed by three booster injections at 2-week intervals. The immune response of the immunized alpacas was monitored by immunoblotting serum samples collected before each booster injection. Although the signals generated in the immunoblots could not be distinguished between conventional immunoglobulins or heavy chain (nanobody) immunoglobulins alone, a positive signal indicated successful immunization and subsequent immune response. After confirming the last booster injection and successful immunization, a phage display library was constructed and screened using established techniques.

[0177] DNA from positive clones was sequenced and a total of 9 clones were selected for further characterization. The relevant VHH sequences were subcloned into the pHEN6 expression vector with certain modifications, i.e. each Nanobody sequence would carry a C-terminal LPETG motif recognized by sortase A and a His6 tag to facilitate recovery and purification ( Figure 17A ). This arrangement enables the installation of fluorophores, biotin or other moieties by site-specific and efficient sortase-catalyzed transpeptidation reactions. Because the LPETG sequence is cleaved during transpeptidation, the His6 tag at the C-terminus of the LPETG motif is lost when the nanobody binds to another moiety. By exhausting the His6-tagged sortase and unreacted input nanobody on a nickel-nitriloacetic acid (NiNTA) matrix, and subsequently recovering the unbound fraction containing the modified nanobody, the desired modified nanobody is enriched. The amino acid sequences of 9 isolated anti-MICA nanobody clones are shown in Table 2 below.

[0178] Table 2: Amino acid sequences of VHHs specific for MICA

[0179]

[0180]

[0181] Nanobodies are not always suitable for immunoblotting experiments; however, when used at a dilution of 1 μg / mL, biotinylated versions of clones A1 and H3 produced unexpectedly strong and specific luminescent signals on immunoblots ( Figure 17B Immunoblots were prepared by resolving whole cell lysate samples spiked with purified MICA*009 antigen by SDS-PAGE, immunoblotting with the isolated nanobody, and treating the immunoblots with streptavidin-horseradish peroxidase (HRP) as a secondary detection agent.

[0182] The specificity of anti-MICA VHH Nanobody binding was further assessed by performing ELISA cross-competition experiments to determine whether the isolated Nanobodies recognized similar or different epitopes on the MICA antigen. Competition of unlabeled Nanobodies with biotinylated Nanobodies for binding to MICA showed that the isolated Nanobodies recognized two different epitopes, one exemplified by the A1 Nanobody and the other exemplified by the H3 Nanobody ( Figure 17CInterestingly, the isolated Nanobodies did not compete with the previously reported 7C6 anti-MICA monoclonal antibody for binding (see, e.g., Ferrari de Andrade et al., Science 2018; 359(6383): 1537-1542), suggesting that these Nanobodies bind to a previously unidentified epitope of the MICA antigen.

[0183] Next, it was assessed whether the isolated anti-MICA nanobody is selective for certain MICA allele products. MICA is a highly polymorphic locus of the human genome, resulting in the expression of multiple allele products in the human population, including several variants associated with disease states (see, e.g., Shi C et al., Open Rheumatol J. 2015; 9: 60-64). Therefore, isolated anti-MICA nanobody may preferentially bind to certain MICA variants rather than other variants. To determine whether this is the case, the binding of A1, B11, E9 and H3 anti-MICA nanobody clones to a panel of MICA variants and similar stress-induced glycoproteins, MHC class I chain-related protein B (MICB) and ferritin controls was assessed in an ELISA assay, and the clones were determined to bind to either of the two different epitopes. Each isolated nanobody was observed to bind to the MICA*008 and MICA*009 variants, but no binding to MICA*002 was observed ( Figure 17D Given that MICA*008 and MICA*009 were observed to appear in slightly more than half of the participants in a study of 1.2 million German donors (see, e.g., Klussmeier A et al., Front Immunol, 2020; 11:314), i.e., in approximately 42.3% and 8.8% of participants, respectively, the isolated Nanobodies will have broad imaging or therapeutic applications in subjects with MICA-expressing tumors.

[0184] To further evaluate whether the isolated anti-MICAVHH nanobodies would bind to MICA on the surface of cells, A1 and H3 nanobody clones were generated for soluble recombinant MICA*009 and cell binding was assessed by flow cytometry. B16F10 melanoma cells transfected to express MICA or MICB, or an empty vector (EV) as a negative control were used to assess binding. Biotinylated A1 and H3 nanobodies were labeled with streptavidin-phycoerythrin (PE) and used for cell fluorescence assays of transfected B16F10 cells. Both A1 and H3 nanobody clones showed robust staining of MICA-transfected cells ( Figure 17E). In addition, neither MICB-transfected cells nor EV-transfected cells were stained by the Nanobody clones, confirming that the isolated Nanobody was able to selectively bind to MICA-positive tumor cells. These results further indicate the utility of the isolated anti-MICA Nanobody, for example, as part of a MICA-specific Nanobody adduct.

[0185] In order to further determine the effectiveness of the isolated anti-MICAAVHH nanobody, additional assays can be performed in vivo. First, the binding of labeled nanobodies can be evaluated in a mouse xenograft model expressing MICA-positive tumors. For example, C57 / B6 mice can be inoculated with MICA-positive B16F10 cells and subsequently treated with biotinylated nanobodies. In view of the fact that mice do not express MICA or cross-reactive species, it is expected that biotinylated nanobodies will only bind to MICA-positive B16F10 tumors. The mice are then treated and imaged with a fluorescent or luminescent agent conjugated with streptavidin. The fluorescent / luminescent signal located at the xenograft site indicates that the labeled nanobody is specific to MICA-positive cancer cells. Second, the isolated nanobody can be further tested as an imaging agent for positron emission tomography (immunoPET) because it is small in size, has efficient tissue penetrance and a short circulation half-life. To test the utility of isolated nanobodies in imaging by immunoPET, C57 / B6 mice can be transplanted with B16F10 control cells or MICA-positive B16F10 cells. Once B16F10 tumors are established, they can then be imaged with 89 Mice were treated with Zr-labeled A1 or H3 nanobody clones and imaged by immunoPET. Figure 17E ), these studies are expected to further demonstrate the diagnostic and clinical applications of these novel anti-MICA nanobodies.

[0186] Example 7 - Evaluation of conjugates

[0187] Tested VHH κ -Biotin and VHH κ -SD36-biotin conjugate binding affinity to mouse immunoglobulin ( Figures 18A-18C). 96-well ELISA high-binding plates were coated overnight at 4°C with 100 μl of 5 μg / ml mouse Ig (mouse IgG isotype control: Invitrogen, catalog number 10400C; mouse IgA isotype control: Invitrogen, catalog number 14-4762-81; mouse IgM isotype control: Biogen, catalog number 401601). The plates were washed three times with wash buffer (PBS supplemented with 0.1% (v / v) Tween-20) and incubated with blocking buffer (PBS with 1% (w / v) BSA) for 1 hour at room temperature. After washing four times with wash buffer, each well was treated with 100 μl of a four-fold serial dilution of VHHκ-biotin, VHHκ-SD36-biotin, or SD36-biotin in blocking buffer. After incubation for 2 hours at room temperature, the plate was washed 4 times with wash buffer and incubated with streptavidin-HRP (1: 1000 dilution, Baijin Company, catalog number 405210) at room temperature for 1 hour. After washing 4 times with wash buffer, each well was incubated at room temperature for 10 minutes with 100 μl of TMB substrate solution (Baijin Company, catalog number 421101), followed by addition of 100 μl of 1N H2SO4 to terminate the enzymatic reaction. The optical density was then read at OD450. The dissociation constant (Kd) was calculated based on the graph of the average absorbance value at 450 nm relative to the concentration of VHH using the saturation binding equation in GraphPadPrism 7. (Saturation binding equation, one site-total amount). These data demonstrate that VHH κ -Biotin and VHH κ -SD36-biotin conjugate has high binding affinity to mouse immunoglobulin.

[0188] VHH κ -Zanamivir, ALB1-Zanamivir, Zanamivir and VHH κ Neuraminidase inhibitory activity against neuraminidase of various influenza species was determined by NA-Star TM The neuraminidase inhibitor resistance assay kit was used to measure the neuraminidase inhibitor resistance of influenza. The neuraminidase inhibitory activity of VHHκ-zanamivir, ALB1-zanamivir, zanamivir and VHHκ was measured by NA-Star TM The influenza neuraminidase inhibitor resistance test kit (Invitrogen, catalog number 4374422) was used for measurement. The influenza strains shown in Figure S12 were used as neuraminidase sources. All viruses were diluted to a signal-to-noise ratio of 40:1 (luminescence intensity of wells containing virus: wells containing NA-Star assay buffer). Briefly, serial dilutions of the test molecule (25 μL) were mixed with 25 μL of NA-Star TMThe virus in the test microplate was incubated at 37°C for 20 minutes. Then 10 μL of NA-Star substrate was added to each well and incubated at room temperature for 30 minutes. Finally, 60 μL of NA-Star promoter solution was added to all wells and the plate was analyzed by microplate reader ( The luminescence intensity was immediately read using iD5 (Molecular Devices). The half-maximal inhibitory concentration (IC50) value was calculated using GraphPad Prism 7. κ -Zanamivir and ALB1-Zanamivir demonstrated half inhibitory concentration (IC50) efficacy ( Figures 19A-19B ).

[0189] The amino acid sequence of ALB1 is:

[0190] AVQLVESGGGLVQPGNSLRLSCAASGFTFRSFGMSWVRQAPGKEPEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLKPEDTAVYYCTIGGSSLRSSQGTQVTVSSGGLPETGGHHHHHH(SEQ ID NO:38)

[0191] Tested VHH κ The ability of SD36 to bind to hemagglutinin expressed on influenza virus-infected MDCK cells. MDCK cells were seeded into 24-well plates and grown overnight to confluence. MDCK cells were infected with influenza virus (10 TCID50) according to the "Manual for the laboratory diagnosis and virological surveillance of influenza" (World Health Organization, 2011).

[0192] Saturation binding assay was used to determine the affinity of VHH to the viral hemagglutinin on the surface of infected MDCK cells. In short, the spent culture medium was aspirated from the 24-well plate containing virus-infected MDCK cells and then replaced with 0.5 mL of fresh serum-free culture medium containing different concentrations of VHHκ-SD36. After incubation for 1 hour at 37°C, the virus-infected cells were rinsed with fresh culture medium (2 × 0.5 mL) to remove unbound VHH. In order to quantify the amount of VHH bound to HA, mouse IgG-phycoerythrin (PE) (1: 20 dilution, R&D Systems, catalog number IC002P) in 0.25 mL of fresh serum-free culture medium was added to the wells containing VHHκ-SD36. After incubation for 30 minutes at 37°C, the virus-infected cells were rinsed with fresh culture medium (2 × 0.5 mL) again and then dissolved in 0.5 mL of 1% (w / v) sodium dodecyl sulfate (SDS). Cell-associated fluorescence was measured using an excitation wavelength of 560 nm and an emission wavelength of 620 nm. The dissociation constant (Kd) was calculated from a plot of cell-bound fluorescence intensity versus VHH concentration using the saturation binding equation in GraphPadPrism 7 (saturation binding equation, per site versus total binding). VHH κ -SD36 binds with high affinity to hemagglutinin expressed on influenza A virus strains ( Figures 20A-20B ).

[0193] Preparation of SD36-DFO and VHH κ -SD36-DFO was used for PET imaging. Nanobody-DFO adducts were prepared by sortase-mediated conjugation of triglycine-modified DFO to nanobodies. SD36-DFO (left) and VHH were analyzed by SDS-PAGE. κ -The final product of SD36-DFO (right).

[0194] Example 8 - In vivo capability of the conjugate

[0195] VHH κ -Zanamivir, MEDI8852, and VHH κ The therapeutic efficacy between -E11 was tested for comparison. 50 Female BALB / c mice aged 6 to 9 weeks were infected with influenza virus. κ - Zanamivir, MEDI8852 (a monoclonal antibody (mAb) that neutralizes both group I and group II influenza A viruses (IAV) in vitro) or VHH κ-E11 (SARS CoV-2 spike-specific nanobody) was treated with mice by intraperitoneal injection. When the mice lost 25% of their body weight or were dying, they were euthanized. Shown are the weight loss curve (left) and the survival rate curve (right). For the weight loss curve, the % change in body weight represents the mean ± standard deviation. The mean value of the % change in body weight of any two groups over 14 days was compared using a one-way ANOVA analysis using Tukey's multiple comparison test. The statistical differences between the specified group and the PBS-treated group are shown (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001). For the survival rate curve, the statistical differences between the specified group and the PBS-treated group were calculated by the log-rank (Mantel-Cox) test (*P<0.05, **P<0.01). These data demonstrate that VHH κ - Zanamivir is superior to MEDI8852 and VHH κ -E11( Figure 21 )

[0196] Example 9

[0197] VHH κ - The ability of zanamivir to induce complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) was tested.

[0198] For CDC assay, 10,000 MDCK cells / well were seeded in 96-well plates and stained with 100 TCID 50 The spent culture medium was aspirated from the 96-well plate containing the virus-infected MDCK cells and then 50 μl of VHH κ - Zanamivir (or VHH κ -SD36) or VHH κ and zanamivir (or SD36) (final concentration: 10 nM) were treated. After incubation at room temperature for 30 minutes, 50 μl of fresh serum-free medium containing 40 μg / mL normal mouse IgG isotype control (Invitrogen, catalog number 10400C) and 40% (v / v) rabbit complement serum (Sigma-Aldrich, catalog number S7764) were added to the cells. The plate was then incubated at 37°C for 2.5 hours. Cell viability was measured using a luminescent cell viability assay (Promega, Cat. No. G7572). Maximum cell killing was achieved by treating cells with 5% H2O2. κ -The percentage of zanamivir-induced cytotoxicity was calculated as follows:

[0199]

[0200] In the presence of rabbit complement and mouse polyclonal mouse IgG, influenza virus-infected MDCK cells were infected with VHH κ - Zanamivir killing, as demonstrated by high cytotoxicity in infected cells ( Figure 23A ).

[0201] For ADCC assay, 10,000 MDCK cells / well were seeded in 96-well plates and treated with 100 TCID 50 The spent medium was aspirated from the 96-well plate containing the virus-infected MDCK cells and then incubated with 25 μl of VHH κ - Zanamivir (or VHH κ -SD36) or VHH κ The cells were treated with a mixture of 10 nM and zanamivir (or SD36) at a final concentration of 10 nM, followed by the addition of 25 μl of 40 μg / mL normal mouse IgG isotype control (Invitrogen, catalog number 10400C). After incubation at room temperature for 30 minutes, 25 μl of ADCC reporter cells (Promega, catalog number 10400C) were added at 75,000 cells / well and incubated at 37°C for 6 hours. In order to measure the luciferase produced by the ADCC reporter cells, 75 μl of Bio-Glo TM Reagent (Promega, catalog number 10400C) was added to each well and the plate was read by a microplate reader ( iD5, Molecular Devices) to measure the luminescence intensity.

[0202] In the presence of VHH κ In the presence of zanamivir and mouse polyclonal mouse IgG, virus-infected MDCK cells induce luciferase expression in reporter cells expressing VHHs with the involvement of the mouse FcγRIV receptor. ADCC induction was calculated by dividing the luminescence intensity of the indicated samples by the mean of the control samples containing virus-infected cells and reporter cells without VHHs. κ and zanamivir mixture, VHH κ -zanamivir conjugates provided significant induction of ( Figure 23B ).

[0203] Discover VHH κ -Zanamivir and ALB1-Zanamivir have similar clearance ( Figure 23DFor each blood draw time point after the initial injection of the construct (x-axis: 10 min, 1 h, 24 h, 48 h, 72 h, 96 h, and 144 h), the number of counts per minute (CPM) of 10 μL of whole blood (y-axis) was calculated. 89 Each individual measurement of the Zr decay rate is shown as a blue square (VHH κ -DFO- 89 Zr, n=3)、red circle (ALB1-DFO- 89 Zr, n = 4) or black triangle (SD36-DFO- 89 Zr, n=3). All mice received an initial dose of 250 μCi 89 Zr-labeled VHH (equal to 1 mg / kg VHH). Each data point represents the mean ± standard deviation. A two-phase decay model was used to estimate the half-life of each VHH (rapid phase and slow phase). Total VHH exposure in the first 144 hours after injection was calculated by integrating the VHH concentration in the blood over time. This is expressed as the 'area under the curve' (AUC).

[0204] Use similar to VHH κ -Experiments with zanamivir revealed that VHH κ -SD36 induces ADCC but not CDC ( Figures 24A-24B ).

[0205] Example 10

[0206] ALB1-zanamivir conjugate was prepared. Figure 25A The anti-serum albumin nanobody (ALB1) has the amino acid sequence shown in . The sortase recognition motif (LPETG) is linked to the C-terminus of the nanobody. ALB1-zanamivir is prepared by sortase-mediated conjugation of triglycine-modified zanamivir to ALB1. The identity of the final product ALB1-zanamivir was confirmed by SDS-PAGE and mass spectrometry ( Figure 25B ).

[0207] Preparation of VHH κ -DFO, ALB1-DFO and SD36-DFO were used for PET imaging. Nanobody-DFO adducts were prepared by sortase-mediated conjugation of triglycine-modified DFO to Nanobody. Nanobody-DFO adducts were analyzed by SDS-PAGE (for each gel, in order from left to right: 1: sortase, 2: unconjugated Nanobody, 3: reaction mixture, 4-9: different fractions obtained after elution from the PD-10 column, Nanobody-DFO adduct shown as #6 on the gel was used for PET imaging).

[0208] Equivalents and scope

[0209] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the embodiments described herein.The scope of the present disclosure is not intended to be limited to the above description, but is instead set forth in the claims that follow.

[0210] Articles such as "a," "an," and "the" may mean one or more unless indicated to the contrary by the context or otherwise obvious from the context. Claims or descriptions that include "or" between two or more members of a group are considered satisfied if one, more than one, or all of the group members are present, unless indicated to the contrary by the context or otherwise obvious from the context. Disclosure of a group that includes "or" between two or more group members provides for embodiments in which exactly one group member is present, embodiments in which more than one group member is present, and embodiments in which all group members are present. For the sake of brevity, these embodiments are not individually set forth herein, but it is understood that each of these embodiments is provided herein and may or may not be specifically claimed.

[0211] It should be understood that the present disclosure covers all variations, combinations, and permutations of introducing one or more limitations, elements, clauses, or descriptive terms from one or more of the claims or from one or more of the relevant sections of the specification into another claim. For example, a claim that is dependent on another claim can be amended to include one or more limitations found in any other claim that is dependent on the same basic claim. In addition, where a claim recites a composition, it should be understood that unless otherwise indicated or unless a contradiction or inconsistency would be obvious to one of ordinary skill in the art, methods of making or using the composition according to any method disclosed herein or according to methods known in the art, if any, are included.

[0212] In the case where an element is presented in a list form such as a Markush group format, it should be understood that each possible subgroup of an element is also disclosed, and any element or subgroup of an element can be removed from the group. It should also be noted that the term "comprising" is intended to be open and allows the inclusion of other key elements or steps. It should be understood that, generally, when an embodiment, product or method is referred to as including a specific element, feature or step, an embodiment, product or method consisting of or substantially consisting of such element, feature or step is also provided. For simplicity, these embodiments are not separately set forth in this article, but it should be understood that each of these embodiments provided herein can specifically claim or not claim protection.

[0213] In the case of providing range, endpoints are included. In addition, it should be understood that, unless otherwise specified or otherwise become apparent according to the understanding of context and / or those of ordinary skill in the art, otherwise the value expressed as range can assume that any particular value in the scope described in some embodiments is 1 / 10th of the lower limit unit of the scope (unless otherwise clearly noted in the context). For the sake of brevity, the value in each range is not separately set forth in this article, but it should be understood that each of these values ​​is provided in this article and can specifically claim or not claim protection. It should also be understood that, unless otherwise specified or otherwise become apparent according to the understanding of context and / or those of ordinary skill in the art, otherwise the value expressed as range can assume any subrange in a given range, wherein the endpoint of the subrange is expressed as the same accuracy as 1 / 10th of the lower limit unit of the scope.

[0214] Where a website is provided, the URL is provided as non-browser executable code with periods between each URL in parentheses. The actual URL does not contain parentheses.

[0215] In addition, it should be understood that any specific embodiment of the present disclosure can be explicitly excluded from any one or more of the claims. Where a range is given, any value within the range can be explicitly excluded from any one or more of the claims. Any embodiment, element, feature, application or aspect of the compositions and / or methods of the present disclosure can be excluded from any one or more of the claims. For the sake of brevity, not all embodiments that explicitly exclude one or more elements, features, objects or aspects are set forth herein.

Claims

1. A conjugate comprising a first agent that binds to an immunoglobulin and a second agent that binds to a target on the surface of a cell or pathogen, wherein the first agent and the second agent are covalently conjugated via a linker.

2. The conjugate of claim 1, wherein the first agent is an antibody fragment comprising a variable region capable of binding to an antigen.

3. The conjugate of claim 2, wherein the antibody fragment comprises a heavy chain variable region.

4. The conjugate of claim 1 or claim 2, wherein the first agent is a single domain antibody fragment. 5 . The conjugate according to any one of claims 1 to 4 , wherein the immunoglobulin bound by the first agent comprises an immunoglobulin kappa light chain or an immunoglobulin lambda light chain.

6. The conjugate of claim 5, wherein the immunoglobulin κ light chain is a human immunoglobulin κ light chain, and the immunoglobulin λ light chain is a human immunoglobulin λ light chain.

7. The conjugate of claim 6, wherein the first agent is bound to the human immunoglobulin kappa light chain.

8. The conjugate of any one of claims 1 to 7, wherein the second agent comprises a small molecule, a peptide, a protein, a carbohydrate, a lipid, a nucleotide, a nucleic acid, an oligonucleotide, an aptamer, or an antibody.

9. The conjugate of claim 8, wherein the antibody is a single domain antibody.

10. The conjugate of any one of claims 1 to 9, wherein the second agent has a therapeutic effect when administered to a subject.

11. The conjugate of any one of claims 1 to 10, wherein the linker comprises a cleavable linker or a non-cleavable linker.

12. The conjugate of claim 11, wherein the linker comprises a cleavable linker.

13. The conjugate of claim 12, wherein the cleavable linker is a peptide linker, a disulfide linker or a hydrazone linker.

14. The conjugate according to any one of claims 1 to 13, wherein the cell is a cell infected by a pathogen, a cancer cell, a transformed cell, a healthy cell, a cell that is undergoing or has undergone a phenotypic change in response to cellular stress.

15. The conjugate according to any one of claims 1 to 14, wherein the pathogen is a virus, a bacterium, a parasite or a fungus.

16. The conjugate of any one of claims 1 to 15, wherein the pathogen is a virus selected from the group consisting of influenza virus, coronavirus, adenovirus, enterovirus, rotavirus, norovirus, herpes virus, lentivirus, poxvirus, paramyxovirus, rhabdovirus, arenavirus, flavivirus, togavirus, hantavirus, pneumovirus, or Ebola virus.

17. The conjugate of claim 16, wherein the influenza virus is influenza A virus or influenza B virus.

18. The conjugate of any one of claims 1 to 17, wherein the second agent binds to influenza virus neuraminidase or influenza virus hemagglutinin.

19. The conjugate of claim 18, wherein the second agent comprises a small molecule that binds to influenza virus neuraminidase.

20. The conjugate of claim 19, wherein the second agent comprises zanamivir or an analog thereof.

21. The conjugate of claim 20, wherein the linker is a triglycine dibenzylcyclooctyne (DBCO) linker.

22. The conjugate of claim 18, wherein the second agent comprises an antibody or antibody fragment that binds to influenza virus neuraminidase.

23. The conjugate of claim 16, wherein the coronavirus is a beta coronavirus.

24. The conjugate of claim 23, wherein the betacoronavirus is Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome (SARS)-related Coronavirus (SARS-CoV)-1, or SARS-CoV-2.

25. The conjugate of claim 24, wherein the second agent binds to the MERS-CoV spike protein, the SARS-CoV-1 spike protein, or the SARS-CoV-2 spike protein.

26. The conjugate of claim 24, wherein the second agent binds to the MERS-CoV spike protein receptor binding domain (RBD), the SARS-CoV-1 spike protein RBD, or the SARS-CoV-2 spike protein RBD.

27. The conjugate of claim 16, wherein the lentivirus is human immunodeficiency virus (HIV).

28. The conjugate of claim 27, wherein the second agent binds to HIV envelope glycoprotein gp120.

29. The conjugate of claim 16, wherein the pneumonia virus is human respiratory syncytial virus (RSV).

30. The conjugate of claim 29, wherein the second agent is associated with the RSV fusion (F) protein.

31. The conjugate of any one of claims 1 to 15, wherein the pathogen is a bacterium selected from the group consisting of Pasteurella, Staphylococcus, Streptococcus, Bacillus, Corynebacterium, Diphtheroids, Listeria, Erysipelothrix, Clostridium, Neisseria, Branhamella, Escherichia, Enterobacter, Proteus, Pseudomonas, Klebsiella, Salmonella, Shigella, Serratia, Acinetobacter, Haemophilus, Brucella, Yersinia, Francisella, Pasteurella, Vibrio, Flavobacterium, Pseudomonas, Campylobacter, Bacteroides, Fusobacterium, Sheathbacter, Streptobacillus, or Legionella.

32. The conjugate according to any one of claims 1 to 15, wherein the pathogen is a parasite selected from the group consisting of Plasmodium, Trypanosoma, Toxoplasma, Leishmania or Cryptosporidium.

33. The conjugate of claim 32, wherein the Plasmodium spp. is Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, Plasmodium knowlesi, Plasmodium ovale subsp. corymbe or Plasmodium ovale subsp. worlichii.

34. The conjugate of claim 33, wherein the second agent binds to a Plasmodium surface protein.

35. The conjugate of claim 34, wherein the Plasmodium surface protein is merozoite surface protein 1 (MSP-1).

36. The conjugate of claim 35, wherein the second agent is an antibody that binds to MSP-1, optionally wherein the antibody is a Nanobody.

37. The conjugate of claim 36, wherein the antibody comprises CDR-H1, CDR-H2 and CDR-H3 of any one of the antibodies listed in Table 1.

38. The conjugate of claim 37, wherein the antibody comprises the amino acid sequence of any one of SEQ ID NOs: 6-17.

39. The conjugate of claim 14, wherein the cancer cell is a blood cancer cell, a lung cancer cell, a breast cancer cell, a brain cancer cell, a gastrointestinal cancer cell, a liver cancer cell, a kidney cancer cell, a bladder cancer cell, a pancreatic cancer cell, an ovarian cancer cell, a testicular cancer cell, a prostate cancer cell, an endometrial cancer cell, a muscle cancer cell, a bone cancer cell, a neuroendocrine cancer cell, a connective tissue cancer cell, a head and neck cancer cell, or a skin cancer cell.

40. The conjugate of claim 14 or claim 39, wherein the second agent binds to a tumor associated antigen.

41. The conjugate of claim 40, wherein the tumor-associated antigen comprises an MHC class I polypeptide-related sequence A (MICA) protein, an MHC class I polypeptide-related sequence B (MICB) protein, a folate receptor, a fibronectin splice variant, an epidermal growth factor receptor (EGFR), a human epidermal growth factor receptor 2 (HER2), a hepatocyte growth factor receptor (HGFR), a vascular endothelial growth factor receptor 2 (VEGFR-2), a CXC chemokine receptor type 4 (CXCR4), a urokinase plasminogen activator surface receptor (uPAR), a follicle stimulating hormone receptor (FSHR), an epithelial cell adhesion molecule (EpCAM), an epithelial cadherin (ECAD), a carcinoembryonic antigen (CEA), or a mesothelin (MSLN).

42. The conjugate of claim 41, wherein the second agent is an antibody that binds to MICA, optionally wherein the antibody is a Nanobody.

43. The conjugate of claim 42, wherein the antibody comprises CDR-H1, CDR-H2 and CDR-H3 of any one of the antibodies listed in Table 2.

44. The conjugate of claim 43, wherein the antibody comprises the amino acid sequence of any one of SEQ ID NOs: 19-27.

45. The conjugate of claim 14, wherein the cell is a cancerous bone marrow cell or a healthy bone marrow cell.

46. ​​The conjugate of claim 45, wherein the second agent binds to a bone marrow-associated antigen.

47. The conjugate of claim 46, wherein the bone marrow-associated antigen is cluster of differentiation antigen 45 (CD45).

48. The conjugate of claim 14, wherein the cell is a cancerous immune cell or a healthy immune cell.

49. The conjugate of claim 48, wherein the cell is a cancerous T cell or B cell, or a healthy T cell or B cell.

50. The conjugate of claim 48 or claim 49, wherein the second agent binds to an immune cell associated antigen.

51. The conjugate of claim 50, wherein the immune cell-associated antigen is cluster of differentiation antigen 4 (CD4), cluster of differentiation antigen 8 (CD8), T cell receptor (TCR) or B cell receptor (BCR).

52. The conjugate of any one of claims 1 to 51, wherein the conjugate provides a therapeutic effect when administered to a subject.

53. The conjugate of any one of claims 1 to 51, wherein the conjugate, when administered to a subject, enhances the association between one or more immune cells expressing a crystallizable fragment (Fc) receptor and the cell or pathogen.

54. The conjugate of any one of claims 1 to 52, wherein the conjugate causes killing of the cell or pathogen when administered to a subject.

55. The conjugate of any one of claims 1 to 54, wherein the conjugate causes inactivation of the cell or pathogen when administered to a subject.

56. The conjugate of any one of claims 52 to 55, wherein the subject is a mammal.

57. The conjugate of any one of claims 52 to 56, wherein the subject is a human.

58. A composition comprising the conjugate according to any one of claims 1 to 57.

59. The composition of claim 58, wherein the composition further comprises a pharmacologically acceptable excipient.

60. A method for enhancing a subject's immune response to a cell or pathogen, the method comprising administering to the subject an effective amount of a conjugate according to any one of claims 1 to 57 or a composition according to claim 58 or claim 59.

61. The method of claim 60, wherein the cell is a cell infected by a pathogen, a cancer cell, a transformed cell, a healthy cell, a cell that is undergoing or has undergone a phenotypic change in response to cellular stress.

62. The method of claim 60 or claim 61, wherein the pathogen is a virus, bacteria, parasite or fungus.

63. The method of any one of claims 60 to 62, wherein the cell is a cell of the subject.

64. The method of any one of claims 60 to 63, wherein the pathogen is a virus selected from the group consisting of influenza virus, coronavirus, adenovirus, enterovirus, rotavirus, norovirus, herpes virus, lentivirus, poxvirus, paramyxovirus, rhabdovirus, arenavirus, flavivirus, togavirus, hantavirus, pneumovirus, or Ebola virus.

65. The method of claim 64, wherein the virus is influenza A virus or influenza B virus.

66. The method of claim 64, wherein the virus is Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome (SARS)-related Coronavirus (SARS-CoV)-1, or SARS-CoV-2.

67. The method of claim 64, wherein the virus is human immunodeficiency virus (HIV).

68. The method of claim 64, wherein the virus is human respiratory syncytial virus (RSV).

69. The method of any one of claims 60 to 63, wherein the pathogen is a bacterium selected from the group consisting of Pasteurella, Staphylococcus, Streptococcus, Bacillus, Corynebacterium, Diphtheroids, Listeria, Erysipelothrix, Clostridium, Neisseria, Branhamella, Escherichia, Enterobacter, Proteus, Pseudomonas, Klebsiella, Salmonella, Shigella, Serratia, Acinetobacter, Haemophilus, Brucella, Yersinia, Francisella, Pasteurella, Vibrio cholerae, Flavobacterium, Pseudomonas, Campylobacter, Bacteroides, Fusobacterium, Sheathbacter, Streptobacillus, or Legionella.

70. The method of any one of claims 60 to 63, wherein the pathogen is a parasite selected from the group consisting of Plasmodium, Trypanosoma, Toxoplasma, Leishmania or Cryptosporidium.

71. The method of claim 70, wherein the parasite is Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, Plasmodium knowlesi, Plasmodium ovale subsp. coryzae, or Plasmodium ovale subsp. worlichii.

72. The method of any one of claims 61 to 63, wherein the cancer cell is a blood cancer cell, a lung cancer cell, a breast cancer cell, a brain cancer cell, a gastrointestinal cancer cell, a liver cancer cell, a kidney cancer cell, a bladder cancer cell, a pancreatic cancer cell, an ovarian cancer cell, a testicular cancer cell, a prostate cancer cell, an endometrial cancer cell, a muscle cancer cell, a bone cancer cell, a neuroendocrine cancer cell, a connective tissue cancer cell, a head and neck cancer cell, or a skin cancer cell.

73. The method of any one of claims 60 to 63, wherein the cell is a cancerous bone marrow cell or a healthy bone marrow cell.

74. The method of any one of claims 60 to 63, wherein the cell is a cancerous immune cell or a healthy immune cell.

75. The method of claim 74, wherein the cell is a cancerous T cell or B cell, or a healthy T cell or B cell.

76. The method of any one of claims 60 to 75, wherein the immune response comprises an innate immune response.

77. The method of any one of claims 60 to 70, wherein the conjugate binds to the cell or pathogen and to an immunoglobulin of the subject, wherein the immunoglobulin further binds to an immune cell of the subject that expresses a crystallizable fragment (Fc) receptor on its surface.

78. The method of claim 77, wherein the immunoglobulin of the subject comprises an immunoglobulin kappa light chain or an immunoglobulin lambda light chain.

79. The method of claim 78, wherein the immunoglobulin of the subject comprises an immunoglobulin kappa light chain.

80. The method of any one of claims 77 to 79, wherein the immune cell is a macrophage, a dendritic cell, a natural killer cell, a neutrophil, a basophil, an eosinophil, or a mast cell.

81. The method of any one of claims 77 to 80, wherein the administration induces the immune cells to produce one or more cytokines or chemokines.

82. The method of claim 81, wherein the one or more cytokines or chemokines are pro-inflammatory cytokines or chemokines.

83. The method of any one of claims 77 to 82, wherein the administration induces phagocytosis of the cell or pathogen by the immune cell.

84. The method of any one of claims 77 to 82, wherein the administration results in killing of the cell or pathogen.

85. The method of any one of claims 60 to 82, wherein the administration causes inactivation of the cell or pathogen.

86. The method of any one of claims 60 to 85, wherein the subject is a subject having or at risk of having a viral infection.

87. The method of any one of claims 60 to 85, wherein the subject is a subject having or at risk of developing cancer.

88. The method of claim 87, wherein the cancer is a metastatic cancer.

89. The method of any one of claims 60 to 88, wherein the subject is a mammal.

90. The method of any one of claims 60 to 89, wherein the subject is a human.

91. The method of claim 90, wherein the subject is a human neonate, human infant, adult, or elderly person.

92. The method of any one of claims 60 to 89, wherein the subject is a companion animal, a research animal, or a domesticated animal.

93. The method of any one of claims 60 to 92, wherein the administration is intravenous, intramuscular, intradermal, subcutaneous, or by inhalation.

94. The method of any one of claims 60 to 93, wherein the administering occurs more than once.

95. The method of any one of claims 60 to 94, wherein the administration is prophylactic.

96. A method for treating a disease in a subject in need thereof or reducing the risk of the subject having a disease, the method comprising administering to the subject an effective amount of a conjugate according to any one of claims 1 to 57 or a composition according to claim 58 or claim 59.

97. The method of claim 96, wherein the disease is caused by a virus, bacteria, parasite, fungus or cancer.

98. The method of claim 97, wherein the virus is an influenza virus, a coronavirus, an adenovirus, an enterovirus, a rotavirus, a norovirus, a herpes virus, a lentivirus, a poxvirus, a paramyxovirus, a rhabdovirus, an arenavirus, a flavivirus, a togavirus, a hantavirus, a pneumovirus, or an Ebola virus.

99. The method of claim 97 or claim 98, wherein the virus is influenza A virus or influenza B virus.

100. The method of claim 97 or claim 98, wherein the virus is Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome (SARS)-related Coronavirus (SARS-CoV)-1, or SARS-CoV-2.

101. The method of claim 97 or claim 98, wherein the virus is human immunodeficiency virus (HIV).

102. The method of claim 97 or claim 98, wherein the virus is human respiratory syncytial virus (RSV).

103. The method of claim 97, wherein the bacterium is Pasteurella, Staphylococcus, Streptococcus, Bacillus, Corynebacterium, Diphtheroids, Listeria, Erysipelothrix, Clostridium, Neisseria, Branhamella, Escherichia, Enterobacter, Proteus, Pseudomonas, Klebsiella, Salmonella, Shigella, Serratia, Acinetobacter, Haemophilus, Brucella, Yersinia, Francisella, Pasteurella, Vibrio cholerae, Flavobacterium, Pseudomonas, Campylobacter, Bacteroides, Fusobacterium, Scabiei, Streptobacillus, or Legionella.

104. The method of claim 97, wherein the parasite is Plasmodium, Trypanosoma, Toxoplasma, Leishmania, or Cryptosporidium.

105. The method of claim 104, wherein the parasite is Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, Plasmodium knowlesi, Plasmodium ovale subsp. coryzae, or Plasmodium ovale subsp. worlichii.

106. The method of claim 97, wherein the cancer is a blood cancer, lung cancer, breast cancer, brain cancer, gastrointestinal cancer, liver cancer, kidney cancer, bladder cancer, pancreatic cancer, ovarian cancer, testicular cancer, prostate cancer, endometrial cancer, muscle cancer, bone cancer, neuroendocrine cancer, connective tissue cancer, head and neck cancer, or skin cancer.

107. The method of claim 97 or claim 106, wherein the cancer is a metastatic cancer.

108. The method of any one of claims 96 to 107, wherein the subject is a mammal.

109. The method of any one of claims 96 to 108, wherein the subject is a human.

110. The method of claim 109, wherein the subject is a human neonate, human infant, adult, or elderly person.

111. The method of any one of claims 96 to 108, wherein the subject is a companion animal, a research animal, or a domesticated animal.

112. The method of any one of claims 96 to 111, wherein the administration is intravenous, intramuscular, intradermal, subcutaneous, or by inhalation.

113. The method of any one of claims 96 to 112, wherein the administering occurs more than once.

114. The method of any one of claims 96 to 113, wherein the administration is prophylactic.

115. An antibody comprising CDR-H1, CDR-H2 and CDR-H3 of any one of the antibodies listed in Table 1.

116. The antibody of claim 115, wherein the antibody comprises the amino acid sequence of any one of SEQ ID NOs: 6-17.

117. An antibody comprising CDR-H1, CDR-H2 and CDR-H3 of any one of the antibodies listed in Table 2.

118. The antibody of claim 117, wherein the antibody comprises the amino acid sequence of any one of SEQ ID NOs: 19-27.

119. An antibody comprising the amino acid sequence of SEQ ID NO:38.